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1. General introduction 
1.1 Thiopurines 
Thiopurines are currently the backbone of childhood acute leukemia treatment. The 
thiopurine antimetabolites, 6-mercaptopurine (6-MP), azathioprine (AZA), and 6-
thioguanine (6-TG) are purine nucleoside analogues.1 6-MP and 6-TG were 
synthesized by Elion and Hutchins in1951 by replacing the oxygen atom at carbon 6 
of hypoxanthine (6-MP) or guanine (6-TG) with sulphur.2 6-MP and AZA are widely 
used immunosuppressants in the treatment of inflammatory bowel disease (IBD) 
such as Crohn‟s disease and ulcerative colitis.3 6-MP‟s earliest use in IBD was 
reported in 1962 for the treatment of ulcerative colitis.4 Currently, about half of IBD 
patients receive thiopurine treatment.5 Both AZA and 6-MP have proven their efficacy 
for the induction and maintenance of remission in active Crohn‟s disease, sparing 
steroids in quiescent steroid-dependent Crohn‟s disease or for preventing recurrence 
after surgery in Crohn‟s disease.5 Due to their broad T-cell effects, AZA and 6-MP 
are effective in blunting autoimmune responses in a variety of diseases, as well as 
preventing allograft rejection in the setting of transplantation.6  
 
1.2 Thiopurine pharmacokinetics and metabolism 
Thiopurines have relatively poor bioavailablility and a short plasma half-life.7 
Standard doses of 6-MP i.e. 75 mg/m2 upon oral administration reach plasma 
concentrations of 0.3 to 1.8 µM within a mean of 2.2 h.2 6-MP has a mean half-life of 
1.9 ± 0.6 h 8 and a bioavailability range of 5-37%.9 While, 6-TG has a bioavailability 
range of 14-46% and a half-life of 90 min. After oral administration at commonly used 
doses of 20 mg/m2, 6-TG reaches peak plasma levels of 0.03 to 5 µM in 2-4 h. AZA 
(oral, 2 mg/kg/day) produces a peak plasma concentration of 6-MP i.e. 75 ng/ml 
(55% of AZA‟s molecular weight is 6-MP) and has a plasma half-life of less than 2 h. 
Intestinal absorption of AZA ranges from 50 to 72% and once absorbed 88% is 
rapidly converted to 6-MP and S-methyl-4-nitro-5-thioimidazole. Rest 12% of S-
methyl   4-nitro-5 thioimidazole is excreted in urine.10  
Thiopurines are pro-drugs and have to undergo extensive metabolism in order to 
exert their cytotoxic action (Fig. 1.1).11 Glutathione S-transferases i.e. A1, A2 and M1 
(GST) catalyze reduction of AZA to 6-MP.12  6-MP intra-cellular uptake is carried out 
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by nucleoside transporters (i.e. SLC28A2, SLC28A3, SLC29A1 and SLC29A2).13 
Three competing pathways convert 6-MP into its various metabolites; catalyzed by 
xanthine oxidase (XO), thiopurine S-methyltransferase (TPMT), and 
hypoxanthine/guanine phosphoribosyl transferase (HGPRT).14 The first pathway is 
catalyzed by XO, which oxidizes 6-MP to produce the inactive metabolite thiouric acid 
(TUA) which is excreted in urine. XO is inhibited by allopurinol. Combination therapy 
with allopurinol causes consequent shunting of 6-MP to two other alternative 
pathways.15 The second major pathway for 6-MP is TPMT catalyzed S-methylation, 
the product of this reaction is 6-methylmercaptopurine (6-MeMP). S-
adenosylmethionine (SAM) is the methyl donor in TPMT reactions; it is formed within 
the folate cycle by 5, 10-methylenetetrahydrofolate reductase (MTHFR).5,16 Through 
the purine salvage pathway, HGPRT metabolizes 6-MP to 6-thioguanosine 
triphosphate (6-TGN).17 Intracellular 6-TGN is incorporated into DNA instead of 
guanine nucleotides, which, after strand breakage, triggers cell-cycle arrest and 
apoptosis.18 6-TG is also a substrate of these three pathways19 but, in contrast to 
AZA and 6-MP, 6-TG is directly metabolized to 6-TGN by bypassing rate-limiting 
intermediate metabolic steps.19,20 HGPRT converts 6-TG into thioguanosine 
monophosphate (TGMP) and by subsequent kinase activity, thioguanosine 






Figure 1.1: Metabolism of thiopurines. 6-MP is formed by non-enzymatic removal of the AZA 
imidazole ring. 6-MP can be further metabolized through three competing pathways. Inactivation of 6-
MP to 6-methyl mercaptopurine (6-MeMP) catalyzed by TPMT through S-methylation is one of these 
pathways. In a second pathway, XO catalyzes inactivation of 6-MP to thiouric acid (TUA). TPMT and 
XO dependent inactivating pathways compete with the hypoxanthine/guanine phosphoribosyl 
transferase (HGPRT) pathway. HGPRT catalyzes salvage of 6-MP and 6-TG to their respective 
monophosphates i.e. thioinosine monophosphate (TIMP) and thioguanine monophosphate (TGMP). 
TPMT methylates TGMP to methylated thioguanine monophosphate (MeTGMP). TGMP and MeTGMP 
bases are converted to thioguanine nucleotides (6-TGN (or dTGTP)) by the sequential action of 
kinases and reductases. TPMT also methylates TIMP and the methylated product MeTIMP is a potent 
inhibitor of de novo purine synthesis (DNPS). TIMP which escapes from TPMT action is converted to 
TGMP by inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate 
synthatase action (GMPS).
21-23
 dTGTP can be incorporated into DNA. The mismatches generated are 
further processed by mismatch repair which results in cell cycle arrest and apoptosis. Thioguanine 
triphosphates (TGTP) can bind with Rac1 instead of guanosine triphosphates (GTP) and inhibit its 




1.3 Thiopurine cytotoxicity  
1.3.1 6-TGN incorporation into DNA 
The final end product of 6-TG and 6-MP intracellular metabolism is 6-TGN (or 
dTGTP). Thiopurine cytotoxicity is exerted by the incorporation of 6-TGN (or dTGTP) 
into DNA and RNA. dTGTP is incorporated by DNA polymerases into DNA and acts 
as a culprit base causing DNA damage. Major cytotoxicity occurs during S-phase by 
the non-enzymatic methylation of DNA incorporated dTGTP by SAM.13 During 
replication 6-MeTG preferentially base pairs with thymine. The 6-MeTG: T base pairs 
resemble replication errors and identified by post-replicative mismatch repair (MMR). 
Intervention and processing of mismatches by post-replicative MMR cause DNA 
damage which trigger DNA damage-related cell cycle checkpoints and consequently 
cell arrest in the G2 phase of the cell cycle.24  
Substitution of dGTP for dTGTP destabilizes DNA locally and increases the opening 
rate of modified base pairs. This decreased stability of TG*C base pairs has 
physiological significance. More single stranded or open conformation allows easy 
excess and recognition of lesions by high-fidelity DNA polymerase and mismatch 
repair proteins or other downstream cytotoxic factors.25 The TG*T base pairs show a 
wobble conformation at the lesion site which changes the thermal dependence of 
base pairs. Surprisingly, TG*T shows more stability than TG*C base pairs, which may 
contribute to the accumulation of more mismatches.26  
After dTGTP incorporation, nucleic acid is more vulnerable to high oxidation reactions 
due to accelerated thio-base reactivity. Exposure of thio-base containing DNA double 
helix to UVA causes destabilization and induces mutagenic changes. MMR deficient 
cells will be thiopurine resistant and more prone to develop therapy related cancer 
after UVA exposure due to accumulation of unrepaired mutations.27  
 
1.3.2 Induction of autophagy 
Autophagy (macroautophagy) functions as a tumor suppressor mechanism and is a 
response to some anticancer DNA damaging agents such as ionizing radiation, 
temozolomide and 6-TG. The DNA mismatches induced by 6-TG are repaired by 
MMR and the resultant DNA strand breaks activate the autophagy pathway. This 
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induction of autophagy may inhibit apoptotic cell death by degrading damaged 
mitochondria but excessive autophagy may ultimately lead to type II programmed cell 
death.28 6-TG induced autophagy is positively regulated by mTOR-S6K1 through its 
negative feedback inhibition of Akt. If 6-TG is used in combination with rapamycin, 
modulation of the mTOR pathway by rapamycin can reduce the antitumor activity of 
6-TG.29 
 
1.3.3 6-TGN inhibition of the Rac1-Vav pathway 
 AZA acts as an inhibitor of Rac1 activation after CD28 co-stimulation (Fig. 1.2). 
dTGTP binds with small GTPases instead of GTP and modulates their activity. 
Binding of dTGTP with Rac1 along with CD28 co-stimulation of T-cells results in 
inhibition of dTGTP exchange with dTGDP. Blockade of Rac1 activation suppresses 
downstream gene targets i.e. STAT-3, mitogen-activated protein kinase kinase 
(MEK), NF-КB and bcl-xL, leading to a mitochondrial pathway of apoptosis. 
Azathioprine converts a co-stimulatory signal by CD28 into an apoptotic signal by 
modulating Rac1 activity. Taken together, AZA achieves immunosuppression by 
modulation of Rac1 activation and consecutive induction of T-cell apoptosis. 
Moreover, AZA induced apoptosis affects mainly CD45RO or T-cells upon CD28 
costimulation, hence AZA treatment is particularly effective in treatment of 
autoimmune and chronic inflammatory diseases.30 
 
Figure 1.3: A hypothetical model for AZA 
mediated immunosuppression. In primary 
CD4+ T cells, CD28 costimulation triggers 
an AZA activated mechanism. CD28 
costimulation causes replacement of Rac1-
bound GDP with GTP by Vav activation. 
Rac1 activates MEKK/IκB/NF-κB and STAT-
3 pathways, both of which result in 
enhanced bcl-xL levels, which in turn 
provide an antiapoptotic signal. 6-Thio-GTP 
from AZA, 6-MP and 6-TG, binds to Rac1 
and blocks Rac1 activation which ultimately 
suppresses bcl-xL expression through 
inhibition of STAT-3 and NF-κB activation, 
followed by a mitochondrial pathway of 
apoptosis. MAP, mitrogen-activated protein; 
IκB, inhibitor of NF-κB. IKK; IκB kinase; 
13 
 
MAPKK; MAPK kinase kinase; MAP3K, MAPKK kinase.
30
 
Thiopurines can also produce immunosuppressive effects by modulating T-cell APC 
conjugation through inhibition of Vav guanosine exchange activity on Rac proteins 
(i.e. Rac1 and Rac2). This inhibition of Vav activity causes over-time accumulation of 
6-TGDT loaded, inactive Rac proteins. In the absence of apoptosis, this blockade of 
Rac activation leads to blockade of ezrin-radixin-moesin dephosphorylation in 
primary T-cells and suppression of T-cell APC conjugation.31 
 
1.3.4 Inhibition of de novo purine synthesis (DNPS) 
Inhibition of DNPS by 6-MP contributes to its cytotoxic effects on T-cells. Methylation 
of TIMP by TPMT produces MeTIMP, which is an efficient non-competitive inhibitor of 
phosphoribosyl pyrophosphate amidotransferase (PPAT). An early step in the 
biosynthesis of purine is catalyzed by PPAT. Inhibition of DNPS by 6-MP treatment 
has an anti-metabolite effect; causing reduction of purine triphosphates available for 
DNA and RNA synthesis, cellular metabolism and signaling. This is thought to 
compromise the clonal expansion of T-cells.27 Some clinical studies do not support 
the role of DNPS inhibition in thiopurine induced immunosuppression. For example, 
Dervieux et al did not find any difference in rates of DNPS in 6-MP treated and 
untreated patients.32 
 
1.4 Cellular targets of thiopurines 
Gene expression profiles after thiopurine exposure suggest interesting targets of 
these drugs. In 6-MP treated mice, gene expression profiles in the liver showed 
significant changes which were time and dose independent. These differentially 
expressed genes belonged to eight functional categories i.e. lipid metabolism, lipid 
transport, cytoskeleton organization and biogenesis, inflammatory response, 
response to stress, oxidation, cell death and ribosome biogenesis.33 
 
The accumulation of 6-TGN is a marker of the outcome of thiopurine therapy in acute 
lymphoblastic leukemia (ALL) patients. Genes associated with 6-TGN can be helpful 
to understand inter patient variability in terms of 6-TGN accumulation. Gene 
expression patterns of ALL patients that accumulated high compared with low 
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intracellular concentrations of 6-TGN showed genes significantly associated with 6-
TGN accumulation. Sixty genes were significantly associated with 6-TGN 
accumulation in 6-MP treated patients and 75 genes in a 6-MP+MTX combination 
therapy group, without any gene overlap between the two groups. Genes encoding 
for metabolic enzymes and transporters (e.g. SLC29A1) were mainly associated with 
6-TGN accumulation after 6-MP monotherapy. While in the combination therapy 
group, protein and adenosine triphosphates (ATP)–biosynthesis pathways were 
mainly linked to 6-TGN concentrations.34 
 
Immunosuppressive effects of thiopurines and their molecular targets are of particular 
interest in the outcome of immunosuppressive therapy. Important immune and 
inflammatory response genes are selectively inhibited by AZA exposure in activated 
and quiescent T-cells. These include alpha 4-integrin, TNFRSF7, and TRAIL. TRAIL 
is similarly inhibited by 6-MP and 6-TG which suggests that this effect is likely 
mediated by 6-TGN.35 
 
Resistance to thiopurines has become a major concern in connection with their use in 
chemotherapy. Comparison of resistant leukemic cell lines to their parental wild type 
cells showed altered expression of nucleoside transporters, purine metabolic 
enzymes (including adenylate kinase 3-like 1 and guanosine monophosphate 
synthetase), deoxynucleotidyl transferase (DNTT) and a specialized DNA 
polymerase.36  
 
1.5 Adverse effects of thiopurines 
The adverse effects of thiopurines can be divided into dose-independent or 
pharmacologically explainable dose-dependent events. During 6-MP/AZA therapy the 
incidence of dose-independent adverse effects is 1.0-6.5%. These include rash, 
arthralgia, hepatitis, myalgia, flu-like symptoms, gastrointestinal complaints, fever, 
and pancreatitis. 6-TG induced dose-independent adverse effects are more frequent  
(approximately 20%), and include  gastrointestinal disturbances (8.4%), 
hepatotoxicity (4%), pancreatic toxicity (1%), general malaise (4.2%), allergic 
reactions (1%) and non- classified adverse events (7.4%).37 In dose-dependent 
reactions, nausea, general malaise and myelosuppression are the most common. 
The incidence of myelosuppression is approximately 3% per patient per year of 
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treatment. Severe myelotoxicity is less frequent; 1% chance per patient per year of 
treatment with a mortality risk of less than 0.1%. In IBD patients bone marrow toxicity 
may develop at any time after starting AZA/6-MP therapy, but the incidence is highest 
during the first few months of therapy.38 Thiopurine induced myelosuppression can 
result in increased morbidity, hospitalization and treatment discontinuation. 
Myelosuppression increases an individual‟s risk of developing an infection and 
sepsis. The incidence of mild leucopenia is approximately 5-25%. Severe leucopenia 
can develop suddenly and unpredictably in approximately 3% of patients. A 27-year 
analysis showed that AZA contributed to the development of myelosuppression in 5% 
of patients. In an 18-year period, 2% of patients with IBD experienced 6-MP-induced 
leucopenia. Myelosuppression occurred more frequently during the first eight weeks 
of therapy with higher drug doses.39 High erythrocyte 6-TGN concentrations correlate 
not only the incidence of leucopenia and myelotoxicity but also with a good 
prognosis, while low concentrations are associated with a higher risk of relapse.10     
6 -TGN plays important role in the induction and remission maintenance therapy of 
myeloid leukemia.40 After administration of 6-MP, the most important factor 
influencing intracellular accumulation of 6-TGN is the variation in the activity of TPMT 
which is a result of well-characterized genetic polymorphisms. The intracellular 
concentration of 6-TGNs and TPMT activity are inversely proportional to each other. 
High activity results in lower concentrations and hence can cause treatment failure in 
children with ALL.41,42 Erythrocyte concentrations of 6-TGN and TPMT activities are 
measured in children with ALL as a reflection of these corresponding parameters in 
target leukemic cells. Relapse has been reported in patients with low erythrocyte 
concentration of 6-TGNs.43 Increasing 6-MP doses in children with wild-type 
metabolic phenotypes could help to avoid relapse.44 Myelosuppression and 
hepatotoxicity are two complications encountered more frequently in patients with low 
TPMT activity and high 6-TGNs. Reduction to 6–10% of the standard thiopurine dose 
is recommended for patients that are homozygous for a non-functional TPMT allele. 
However for heterozygous patients an initial full dose can be recommended but is 
more likely to require dose reduction to reduce the risk of toxicity.44 
 
1.6 Thiopurine S-methyltransferase (TPMT) 
Thiopurine S-methyltransferase (TPMT) is an S-adenosyl-L-methionine dependent 
enzyme that catalyzes S-methylation of aromatic heterocyclic sulfhydryl compounds 
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including anticancer and immunosuppressive thiopurines. Chromosome 6p22.3 
contains the human TPMT gene which is 34 kb in length and consists of 10 exons 45 
along with a pseudo-gene localized on chromosome 18.46 Also a processed 
pseudogene of TPMT with 96% homology to the TPMT gene is located on 
chromosome 18q21.1. Within the 5´ promoter region there is a 71% GC content (from 
–873 to +736) and no consensus sequences for TATA box or CCAAT elements but 
several binding sites for well-characterized transcription factors including Sp1, NF-κ, 
AP-2 and KROX-24. Variable number tandem repeats (VNTRs) have been identified 
in the 5´UTR and several studies have been carried out to elucidate the importance 
of these VNTRs. To date no strong link between the number of VNTRs and TPMT 
activity has been reported.10 The product of the TPMT is a 28 kDa monomeric, 
single-domain protein consisting of a nine-stranded core β-sheet sandwiched 
between two sets of α-helices.47  
 
 
1.7 TPMT as an enzyme 
TPMT is a cytosolic methylating enzyme (E.C. 2.1.1.67) with the highest levels in 
liver and kidney and relatively low levels in brain and lungs. Levels of TPMT activity 
in red blood cells (RBC) correlate highly with activity in other human tissues (liver, 
kidney) and cells (lymphocytes). Erythrocytes TPMT activity in healthy males is 8.3% 
higher than in healthy females. Similarly, RBC TPMT activity in newborns is higher 
(about 50%) than in healthy adults. In children and adults, there is no difference in 
TPMT activity in different age groups.48 Gender and nicotine consumption correlated 
with TPMT activity in a Northern European Caucasian population. In males TPMT 
activity was 7% higher compared to females, while, male and female smokers had 
4% and 6% higher TPMT activity compared to non-smokers, respectively.49 An 
increase in RBC TPMT activity was observed while on 6-MP therapy but this increase 
reverted to normal when therapy was stopped.43 Recently a contradictory observation 
was reported, where 6-MP treatment resulted in VNTR architecture-dependent 
decrease in TPMT gene expression.50 Determination of TPMT activity after the 
initiation of thiopurine therapy could be misleading since TPMT activity at the end of 
six months of treatment did not correlate with the ratio of 6-MeMP/6-TGN.51 The 
endogenous substrate for TPMT is not known, hence, its biological role remains 
unidentified. The only known substrates are exogenous i.e. thiopurine drugs. Without 
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thiopurine exposure TPMT activity variation has no apparent consequences.16 
However, some non-steroidal anti-inflammatory drugs like naproxen, mefenamic and 
tolfenamic acid inhibits TPMT activity in a non-competitive manner. Weak inhibition of 
TPMT by ketoprofen and ibuprofen has also been observed. Olsalazine, 5-
aminosalicylic acid and sulphasalazine are also non-competitive inhibitors of TPMT.48 
 
1.8 TPMT polymorphism  
The observed variation in TPMT activity is largely the result of single nucleotide 
polymorphisms (SNPs). Some of the polymorphisms result in decreased TPMT 
activity compared with the wild-type sequence (TPMT*1).10 More than 30 allelic 
variants of the TPMT gene have been identified to date.16 Some of these alleles 
contain point mutations leading to amino acid substitutions (TPMT*2, -*3A, -*3B, -
*3C, -*3D, -*5, and -*6), formation of a premature stop codon (TPMT*3D), or 
destruction of a splice site (TPMT*4).52 Three SNPs associated with loss of catalytic 
activity are responsible for the most cases of TPMT deficiency i.e. TPMT*2 (c.238G > 
C, Ala80Pro) TPMT*3B (c.460G > A, Ala154Thr), and TPMT*3C (c.719A > G, 
Tyr240Cys), (Fig. 1.3).53,54 Significant reduction in enzyme activity due to enhanced 
rates of proteolysis is observed in Caucasians due to the presence of TPMT*2 (238 
G > C), TPMT*3A (460 G > A, 719 A > G) and TPMT*3C (719 A > G), accounting 
together for 80–95%, of the polymorphic alleles.55 In Caucasians TPMT*3B (460G > 
A) occurs rarely. However, in other ethnic populations there is a variation in the 
frequency of these alleles.56 The most frequent mutation in those of African or East or 
Southeast Asian origin is TPMT*3C whereas, all other known variants are rare.57 
Deletion of exon six and nine 58 and polymorphisms in the variable number of tandem 




Figure 1.3: TPMT alleles. TPMT*1 is the most common allele („wild type‟), while 
TPMT*3A is the most common variant allele in Caucasian subjects and TPMT*3C is the most 
common variant allele in East Asian subjects. Black rectangles represent the open reading 
frame (ORF) while open rectangles represent 5´ and 3´ untranslated region (UTR) sequence. 
„VNTR‟ represents a GC-rich variable number of tandem repeats that is located in the 5´ 
flanking region of the gene.60 
 
Depending upon the presence of mutant allele activity, patients are categorized as 
high, intermediate or deficient.55,61-64 Individuals with both normal alleles (TPMT*1) 
have high TPMT activity, homozygotes for a variant allele (e.g. TPMT*3A/*3A) have 
negligible TPMT activity, whereas heterozygotes (e.g. TPMT*1/*3A) have activity that 
is approximately half of normal.57  
In patients treated with thiopurines, TPMT genetic polymorphism is a key factor 
responsible for serious adverse drug reactions (myelosuppression) and may also 
contribute to individual variation in therapeutic efficacy.65 An adverse interaction has 
been observed between TPMT polymorphisms, thiopurine therapy, and cranial 
irradiation. Among those who received cranial irradiation and thiopurine therapy, the 
cumulative incidence of brain tumors was 40% in patients who were TPMT-deficient 
versus 8.3% in those with wild-type TPMT activity.66 In TPMT heterozygous IBD 
patients genotype strongly predict gastric intolerance and bone marrow toxicity. No 
significant correlation was observed in IBD patients between TPMT polymorphisms 




1.9 TPMT in vivo and in vitro models 
In vivo and in vitro models serve as simple systems to understand the role of TPMT 
polymorphism in thiopurine metabolism and efficacy. Hartford et al, established a 
mouse TPMT knockout model with TPMT-/- and TPMT+/- genotypes.68 They performed 
pharmacokinetic and pharmacodynamics studies on knockout and wild type TPMT+/+ 
mice treated with 6-MP and 6-TG. Although this murine model was very close to the 
TPMT gene polymorphism in patients, the drug doses used for their experiments 
were very high (i.e. 100 mg/kg/day of 6-MP, 5 mg/kg/day for 6-TG). These amounts 
are much higher than those used in clinical practice, hence results from this study 
may not be predictive of the effects of TPMT polymorphism on outcomes in patients.  
A cell culture model of exogenous or induced expression of TPMT in CCRF-CEM 
cells and in an embryonic kidney cell line showed increases of 14 fold and 3.8 fold in 
TPMT activities respectively.69-71 These TPMT overexpressing cells were exposed to 
6-MP and 6-TG to examine the sensitivity of cells and measure the accumulation of 
intracellular metabolites. Comparison with normal TPMT expression in non-
transfected cells revealed changes in sensitivity to these drugs and also in metabolite 
concentrations as a result of TPMT overexpression. These models do not correlate 
with the natural situation in patients, TPMT polymorphisms exhibit normal and 
reduced TPMT activity in humans. In these studies comparisons were made between 
normal and high activity. In order to address the important phenomenon of TPMT 
polymorphisms and their implications in human thiopurine therapy, a TPMT 
deficiency model would be the better choice. 
 
1.10 Rationale of study 
We developed an in vitro cell line based TPMT knockdown model which is analogous 
to the phenomenon of human TPMT polymorphism which could help to understand 
the significance of TPMT polymorphisms in thiopurine therapies. We further 
assessed this model through growth inhibition assays, apoptosis assays and 
estimation of metabolites accumulation. Further, we used 2-DE and mass 
spectrometry to identify proteomic targets of thiopurine therapy and TPMT variable 
expression. This work may help to better understand the correlation between the 
thiopurine therapy and TPMT polymorphisms in humans and could provide a step on 




2. Establishment of Thiopurine S-
methyltransferase (TPMT) gene knockdown in 
Jurkat T-lymphocytes:  An in vitro model of 
TPMT polymorphism. 
Misbah Misdaq1, Reiner Andag1, Michael Oellerich1, Abdul R. Asif1§*, Nicolas von Ahsen1,2*. 
1. Department of Clinical Chemistry, University Medical Centre Goettingen, 37075, 
Goettingen, Germany. 
2. Medizinisches Labor, 28357 Bremen. 













Published in “Ther Drug Monit” 2012; 34:584–592 
Promotional and commercial use of the material in print, digital or mobile device format is 
prohibited without the permission from the publisher Lippincott Williams & Wilkins. Please 








 Thiopurine S-methyltransferase (TPMT) is an excellent example of an enzyme whose 
pharmacogenetic polymorphisms affect efficacy and toxicity of a drug. The association 
between TPMT activity and thiopurine related myelosuppression is well recognized. To study 
the significance of TPMT deficiency in thiopurine metabolism and immunosuppressive 
activity in vitro, we established RNA interference-based TPMT knockdown (kd) in a Jurkat 
cell line.  
2.1.2 Results 
 In Jurkat TPMT kd cells TPMT expression was reduced to 73% at the RNA level and 83% at 
the protein level. TPMT kd cells were more sensitive to 6-mercaptopurine (6-MP, 10 µmol/L) 
and 6-thioguanine (6-TG, 8 µmol/L) than wild type (wt) cells, (32% vs 20%) and (18% vs 9%), 
respectively. Both Jurkat wt and kd cells were more sensitive to 6-TG induced apoptosis than 
to 6-MP. 6-TG activity was also more affected by TPMT levels than was 6-MP as reflected by 
IC60  concentrations i.e. 6-MP [4.6 µmol/L (wt) and 4.7 µmol/L (kd)], 6-TG [2.7 µmol/L (wt) and 
0.8 µmol/L (kd). IC60 concentrations induced significant apoptosis in both Jurkat wt and kd 
cells (257%, vs 314%) with 6-MP and (323% vs 306%) with 6-TG, respectively. At IC60 (6-
MP) 6-thioguanine nucleotides (6-TGN) accumulation in cells was 518 vs 447 pmol/million 
cells in wt and kd cells, respectively. On the other hand 6-TGN accumulation at IC60 (6-TG) 
was 477 vs 570 pmol/million cells in wt and kd cells, respectively. 6-Methylated 
mercaptopurine (6-MeMP) concentrations were more affected than 6-TGN by TPMT 
knockdown (194 vs 10 pmol/million cells) in wt and kd cells, respectively. 
2.1.3 Conclusion 
 We conclude that TPMT knockdown cells are an appropriate in vitro model to investigate the 
significance of TPMT deficiency with thiopurine therapy and could be helpful in 











Thiopurines are drugs of choice for childhood leukemia, inflammatory bowel disease, and 
renal transplants. Thiopurine S methyltransferase (TPMT), a cytosolic enzyme, modulates 
the efficacy of thiopurine therapy by its S-methylation of various thiopurines. TPMT controls 
one of the three competing thiopurine metabolic pathways. The other two pathways are 
xanthine oxidase (XO) catalyzed thiouric acid production and 6-TGN production by a 
multistep process initiated by hypoxanthine guanine phosphoribosyltransferase (HGPRT).72  
Thiopurine cytotoxicity is the result of 6-TGN incorporation into DNA and RNA.73 The net 
concentration of 6-TGN depends on the relative activity of competing enzymes for the 
metabolism of thiopurines i.e. XO, HGPRT and TPMT. Success of therapy is attributed to the 
balance between the production of 6-TGN and 6-MeMP and this balance is significantly 
influenced by genetic polymorphisms of TPMT.74 There is a trimodal distribution of TPMT 
activity in the general population that results in large, inherited variation in enzyme activity, 
ranging from high to virtually undetectable levels.49,75 TPMT has monogenic co-dominant 
inheritance and substantial ethnic differences in the frequencies of low-activity variant alleles 
of TPMT have been reported.76-79 Lack of TPMT activity is associated with therapy-related 
myelosuppression and high TPMT activity can cause treatment failure.75 Less efficient 
methylation due to TPMT deficiency leads to increasing levels of active metabolites and 
thereby to increased risk of hematopoietic toxicity.80 (For a brief drug metabolism pathway 
see Fig.1.1) Studies on the molecular genetics mechanisms involved in TPMT regulation 
have added a great deal to the understanding of clinical implications of TPMT polymorphism. 
However, there are still unanswered questions regarding the mechanisms responsible for 
thiopurine induced toxicity and TPMT effects.   
A number of in vitro systems have been used to conduct pharmacokinetic and 
pharmacodynamic studies using cell culture models that differentially express TPMT.69,81,82  
In these cell culture models different exogenous expression techniques were used to 
establish stable and inducible TPMT expression.  Elevated expression was compared with 
normal or basal expression in terms of the cytotoxicity of thiopurines and relative metabolite 
accumulation.69,82 These studies have one common finding: that elevation of TPMT activity 
rendered the cells less sensitive to 6-TG, but more sensitive to 6-MP. However, it is difficult 
to extrapolate these results to the clinical situation because of differences in the absolute 
level of TPMT activity between that in over expressed cells and activity measured in patients. 
Patients homozygous for alleles that result in low TPMT activity have significantly less 
23 
 
enzyme activity than normal. Drawing a comparison between very high activity and normal 
activity does not actually mimic the phenomenon of TPMT polymorphism. 69,82  
The best possible representation of any polymorphism such as occurs with TPMT would be a 
gene knockout or knockdown model.  Analysis of gene function using dsRNA induced 
silencing is a powerful tool through which stable and inducible suppression of genes of 
interest can be established in diverse systems. This strategy is being widely used for the 
identification of targets for treatment of diseases through genome-wide screening,83 
treatment of viral infections,84 and for cancer drug discovery.85 We sought to establish a 
TPMT deficiency model that would more accurately represent TPMT polymorphism. We 
transfected a TPMT specific shRNA expressing plasmid in T-lymphocytes and selected 
stable clones exhibiting efficient TPMT knockdown. Comparison of responses in wild type to 
those in these knockdown cells after thiopurine challenge provides greater understanding of 




Figure 2.1: Schematic representation of thiopurines metabolism and effects of 
TPMT knockdown.  A. Azathioprine (Aza) is converted non-enzymatically to 6-
mercaptopurine (6-MP) which can be further metabolized through three competing pathways. 
Thiopurine S methyltransferase (TPMT) by S-methylation inactivate the 6-MP to 6-methyl 
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mercaptopurine (6-MeMP). Second, xanthine oxidase (XO) catalyze inactivation of 6-MP to 
thiouric acid (TU). These TPMT and XO dependent inactivating pathways compete with 
hypoxanthine phosphoribosyl transferase (HPRT) pathway which catalyze salvaging of 6-MP 
to thioinosine monophosphate (TIMP). HPRT pathway also metabolize the 6-thioguanine (6-
TG) to its respective monophosphate i.e. thioguanine monophosphate (TGMP). TPMT 
methylates TGMP to methylated thioguanine monophosphate (MeTGMP). TIMP is also 
substrate of TPMT and its methylated product MeTIMP is a potent inhibitor of purine de novo 
synthesis. TIMP which escapes from TPMT action is converted to 6-TGMP by inosine 
monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthatase action 
(GMPS). TGMP and MeTGMP by the sequential action of kinases and reductases converted 
to 6-thioguanine nucleotides (6-TGN) that further incorporate into DNA. Depending on level 
of TPMT activity balance of these competing pathways differs, therefore outcome of Aza, 6-
MP and 6-TG treatment may also differ.21-23 B. Observed effects of TPMT knockdown on 
Jurkat cells. 
 
2.3 Material and methods 
2.3.1 Reagents 
Cell culture medium RPMI, fetal calf serum (FCS), phosphate buffered saline (PBS), 
penicillin, streptomycin and amphotericin B were purchased from PAA Laboratories, Colbe, 
Germany. Ciprobay was obtained from Bayer Vital GmbH, Leverkusen, Germany. 
LipofectamineTM and opti-MEM from Invitrogen, Darmstadt, Germany, were used. 
Dithiothreitol (DTT), 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), sodium carbonate, and 
DMSO were purchased from Sigma-Aldrich, Steiheim, Germany. Sodium dodecyl sulfate 
(SDS) was obtained from Serva, Heidelberg, Germany. Biozym plaque agarose was 
purchased from Biozym scientific GmbH, Hessisch Oldendorf, Germany). Hygromycin was 
purchased from Cayla France.  
 
2.3.2 Cell culture   
The Jurkat cell line was obtained from the German Collection of Microorganisms and Cell 
Cultures (DSMZ), Braunschweig, Germany. Cells were maintained in RPMI supplemented 
with 10% (v/v) heat-inactivated FCS, 100 U/mL penicillin and 0.1 mg/mL streptomycin at 
37°C in a humidified atmosphere of 5% CO2 in 75 cm
2 culture flasks (Sarstedt, Nuembrecht, 
Germany). Jurkat knockdown (kd) cells were maintained under hygromycin selective 
pressure (200 µg/mL). 
2.3.3 shRNA design, cloning and optimization 
For stable knockdown of TPMT, four sets of shRNAs were designed and cloned in pSi 2.1 at 
BamHI and HindIII sites. To monitor TPMT expression change, TPMT cDNA was cloned in 
pSi CHECK-2 at XhoI and NotI sites. Cotransfection of pSi 2.1 and pSi CHECK-2 in 1.5x107 
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CCRF-CEM cells was done by electroporation. After 48 hrs of transfection, decrease in 
TPMT expression was checked by double luciferase assay. The assay was performed using 
firefly and Renilla luciferase assay kits (Biotium, Inc Hayward, CA USA) according to 
manufacturer‟s protocol. Renilla luciferase showed the RNA interference effect of 
cotransfected pSi 2.1 containing shRNA.  
 
2.3.4 Western blotting 
Western blotting was performed according to the previously described method 86, using anti 
TPMT (Abnova, Taipei, Taiwan) and mouse anti actin (Sigma Aldrich, Steinheim, Germany) 
were used in 1:1000 dilution. Densitometric analyses for protein quantification were done 
using LabImage software, version 2.71 (Kapelan, Leipzig, Germany). β-actin was used as a 
loading control and five independent experiments were performed to ensure the 
reproducibility. 
 
2.3.5 RNA isolation, cDNA synthesis and real time PCR  
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer‟s protocol. Briefly, cells were harvested, washed and homogenized in Trizol 
reagent. RNA quality and quantity were assessed by NanoDrop 2000 (Thermo Fischer 
Scientific Inc.). 3 µg RNA was used for reverse transcription in a 30 µL reaction mix 
containing 1x reverse transcriptase (RT) PCR buffer (10 mmol/L Tris-HCL,  pH 8.3, 15 
mmol/L KCl, 0.6 mmol/L MgCl2), 0.5 mmol/L of dNTPs mix, 1U/µL RNase inhibitor and 13.3 
U/µL M-MLV RT enzyme. The reverse transcription step was performed in a thermocycler 
(Biometra, Goettingen, Germany) at 42°C for 1 hr. cDNA was stored at - 70°C until use. 
Relative, quantitative PCR was carried out using the LightCycler instrument (Roche 
Diagnostic Systems, Somerville, NJ, USA). The PCR reaction was performed in 20 µL with 
TPMT (forward 5′-CTT CGG GGA ACA TTT CAT TG-3′ and reverse 5′-CCT TTC AAT TTC 
AGC ATG TGG -3′), and elongation factor 2 (forward 5′-GACATCACCAAGGGTGTGCAG-3′ 
and reverse 5′-GCGGTCAGCACACTGGCATA-3) primers. Primer3 software 
(http://frodo.wi.mit.edu) was used for primer design.  The PCR reaction mixture was prepared 
as previously described.87 The fold decrease of TPMT mRNA in transfected cells compared 
with non-transfected control samples was calculated using the comparative threshold cycle 
(CT) method 2-ΔΔ CT.88 The internal control was EF-2. Experiments were performed four times. 
The protocol used was identical for both genes i.e. 30 s 95°C, 35x (1 s 95°C, 5 s 55°C, 10 s 




2.3.6 TPMT enzyme activity assay 
TPMT enzyme activity of Jurkat wt and kd cells (5x106 cells each) was assayed as described 
earlier.89 Samples lacking SAM were used as blanks and five independent experiments were 
performed. TPMT activity was expressed as nanomoles of 6-MeMP formed per 5x106 cells, 
results were further normalized to the protein concentration of the sample to avoid influence 
of any handling error during cell counting and lysis. One unit (IU) of TPMT enzyme activity 
represents the formation of 1nmol of 6-MeMP per hour per microgram of protein. 
 
2.3.7 Proliferation assay 
Cell proliferation was assayed using MTS reagent (Promega Corporation, Madison, WI, 
USA) as previously described.90 Briefly, cells were grown in 24 well plates at a density of 0.1 
x 106 cells/well 24 hrs prior to the start of the experiment. The cells were then incubated with 
DMSO (control) or 0.75 µmol/L to 10 µmol/L 6-MP and 0.25 µmol/L to 8 µmol/L 6-TG for 48 
hrs. Cell viability was estimated on the basis of reduced formazon product formation. The 
IC60 estimation was done using dose-response curve fitting using a non-linear regression 
analysis i.e. log (inhibitor) vs normalized response, using GraphPad Prism Software version 
5.01 (GraphPad Software, Inc.).  
 
2.3.8 Apoptosis assay 
A functional assay for caspase-3 activity was performed using CaspACETMassay kits 
(Promega Corporation, Madison, WI, USA) according to the manufacturer‟s instructions. 
Briefly, after 48 hrs treatment with DMSO, 6-MP and 6-TG cells were collected, lysed with 
reporter lysis buffer (Promega Corporation, Madison, WI, USA). 70 μg of protein lysate was 
added to a reaction mixture containing colorimetric substrate (DEVD-pNA), assay buffer, 
DMSO and DTT followed by overnight incubation at RT.  A specific inhibitor of caspase-3 
provided with kit was used to verify the specificity of the assay. The absorbance of the 
cleaved DEVD-pNA product p-nitroanilide was measured at 405 nm using an EL808 
microplate reader (Bio-Tek instruments, Winooski, VT, USA). Five independent experiments 
were performed. 
 
2.3.9 Metabolite measurements  
Jurkat wt and kd cells were seeded at 0.1x106 cells/mL and treated with IC60 concentrations 
of 6-MP and 6-TG for 48 hrs. After incubation cells were harvested and metabolites (6-TGN 
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and  6-MeMP) were measured by the use of the methods of Lennard and Singleton 91 with 
modifications as described previously.92 Four independent experiments were performed and 
metabolites units were presented as pmol/ 106 cells/hr. 
 
2.4 Results 
Four different sequence specific shRNAs were cloned in psi 2.1 and cotransfected with pSi 
CHECK-2 containing TPMT cDNA in CCRF-CEM cells. A double luciferase assay was 
performed 48 hrs after transfection to check the efficiency of knockdown. The Renilla 
luciferase and TPMT genes are under the control of the same promoter; Renilla luciferase 
activity corresponds to TPMT expression and also represents RNAi induction. Firefly 
luciferase activity serves as a control for normalization. shRNA1 and 3 did not show 
satisfactory knockdown with 63% (p<0.05) and 90% (p=0.29) Renilla luciferase signal, 
respectively (data not shown). shRNAs2 and 4 showed significant levels of TPMT transcript 
degradation and TPMT expression of 42 % (p<0.005) and 33% (p<0.001), respectively (data 
not shown). Then, to further optimize the knockdown efficiency, we tested shRNA 3 and 4 
with a longer stem (29bp) that makes shRNA more potent (Fig 2.2).93 Both shRNAs (3 and 4) 
showed improved efficiency. This was more prominent for shRNA3 which showed 55% 
greater reduction in TPMT expression from 90% to 34%. The second modified shRNA4 was 
also more effective than its precursor; the TPMT signal was reduced from 33% to 25%. 




Figure 2.2: Comparison of the efficiency of different shRNAs using a double 
luciferase assay. Two shRNAs (3 and 4) were compared with their corresponding, longer 
shRNA to check for better knockdown efficiency. Renilla luciferase activity (corresponding to 
TPMT expression) was normalized to the internal control firefly luciferase activity. Data are 
mean ± SD of four independent experiments (*p<0.05, **p<0.005, ***p<0.001). 
 
To establish stable TPMT knockdown in Jurkat T-lymphocytes, psi 2.1 containing TPMT 
specific shRNA (psi 2.1-TPMT) was transfected into Jurkat cells. After 24 hours of 
transfection, cells were transferred to soft agar and allowed to proliferate under hygromycin 
selective pressure for three weeks. Monoclonal colonies were picked and grown. These 
monoclonal cultures were than tested for degree of knockdown at the mRNA level. Out of 
tested clones, one (clone 9) showed maximum fold decrease in TPMT mRNA (mean fold= -
7.27, n=4, p<0.001) compared to non-transfected wild type (wt) controls (Fig. 2.3 a). Only 
clone 9 (described as Jurkat kd) was selected for further confirmation at the protein level by 
Western blot analysis (Fig. 2.3 b). Western blot analysis confirmed the PCR results (mean 
fold=-6.25, n=3, P<0.05). Jurkat knockdown (kd) cells (clone 9) with >80% TPMT knock 










Figure 2.3: Confirmation of TPMT knockdown by real time PCR and Western 
blot analysis. Stable TPMT knockdown cells were generated using RNAi technology. (a) 
Real time PCR analysis for TPMT mRNA expression, EF-2 was used as an internal control 
gene and fold change was determined by 2 -∆C. Data are represented as mean ± SD of four 
independent experiments (***p<0.001). (b) Cultured Jurkat wt and kd cells were harvested 
after different passages, then lysed and TPMT expression was determined by 
immunoblotting. ß-actin was used as the loading control. Band pixel densities of TPMT in 
control and kd cells were calculated with the LabImage software. Data are represented as 
mean ± SD of six independent experiments (*p<0.05). 
 
TPMT activity of Jurkat kd and wt cells were determined at different passages to confirm the 
stability of knockdown (Fig. 2.4). In kd cells TPMT was 1.7U/mg of protein compared to 
6.1U/mg in wt cells (mean fold=-3.56, n=5, p<0.001).  These results from the enzyme activity 
assay correlated well with real time PCR and Western blot results; Jurkat kd cells showed 





Figure 2.4: TPMT enzyme activity of Jurkat wt and kd cells. Enzyme activity 
(equivalent to 6-MeMP concentrations) was determined by HPLC. Data represent mean ± SD 
enzyme activity from five independent experiments, significance (***p<0.001) was 
determined by Student t test. 
To investigate the sensitivity of Jurkat wt & kd cells to thiopurines, cells were treated with 
serial concentrations of 6-MP (0-10 µmol/L) and 6-TG (0-8 µmol/L) for 48 hrs. Cell viability 
was determined by MTS assay. The cells showed dose dependent but different levels of 
sensitivity to 6-MP and 6-TG (Fig. 2.5). Both Jurkat wt & kd cells were more sensitive to 6-TG 
than to 6-MP.  At the maximum 6-MP concentration (10 µmol/L), wt and kd cells showed 32% 
(p<0.001) and 20% (p<0.001) survival, respectively. While after exposure to the maximal 
concentration of 6-TG (8 µmol/L) there was 18% (p<0.001) and 9% (p<0.001) survival in wt 
and kd cells, respectively. IC60 concentrations were calculated from growth inhibition data. As 
6-MP and 6-TG showed different growth inhibition kinetics, dose-response curve fit better for 
both drugs at IC60. IC60 concentrations of 6-TG were 0.8±0.19 µmol/L and 2.7±0.18 µmol/L for 
kd and wt cells, respectively. There was a 72% decrease in IC60 concentration of 6-TG as a 
result of TPMT knockdown. While responses to 6-MP treatment were not much affected by 
TPMT status in wt and kd cells. The 6-MP IC60 concentrations for wt and kd cells were 




Figure 2.5: Growth inhibitory effect of 6-MP and 6-TG on Jurkat wt and kd cells. 
After treatment cell viability was determined by MTS assay. Colored formazon product was 
measured by ELISA plate reader. IC60 values were calculated using a nonlinear regression 
equation using GraphPad Prism software. Data are mean ± SD of five independent 
experiments.  
To investigate the effects of thiopurines on cell apoptosis in cells with low versus high 
TPMT activity, cells were treated with IC60 concentrations of 6-MP and 6-TG for 48 
hrs and caspase-3 activity was determined. Significant induction of caspase-3 activity 
was observed in treatment groups compared to DMSO treated control (Fig. 5). Mean 
increase in absorbance after 4.6 µmol/L 6-MP treatment was 314% (n=4, p<0.001) in 
wt cells and 257% (n=4, p<0.001) after 4.7 µmol/L of 6-MP in kd cells. However, 6-
TG treated wt (exposed to 2.7 µmol/L) and kd cells (exposed to 0.8 µmol/L) showed 
306% (n=4, p<0.001) and 323% (n=4, p<0.001) increases in caspase-3 activity 
compared to controls.  A similar level of apoptosis was observed in kd and wt cells 





Figure 2.6: Thiopurine induced caspase-3 activity in Jurkat wt and kd cells. 
Treated and untreated control cells were lysed and lysates were incubated with caspase-3 
assay reaction mixture. Apoptosis was determined by measuring colored pNA product using 
an ELISA reader. Data are the mean ± SD of four independent experiments and significance 
(***p<0.001) was calculated by Student t test.  
To investigate the effect of TPMT knockdown on thiopurine metabolite accumulation, 
intracellular metabolite concentrations were measured after 48 hrs treatment with 
IC60 concentrations of 6-MP and 6-TG (Fig. 6a, b & c). Jurkat kd cells had a mean of 
447 pmol/106 cells 6-TGN concentration after 6-MP treatment, while wt cells had a 
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mean of 518 pmol/106 cells. 6-TGN mean concentration after 6-TG treatment was 
477 and 570 pmol/106 cells in wt and kd, respectively. 6-MeMP was also measured 
after 6-MP treatment, kd cells had 19 fold less (10 pmol/106 cells, n=4, p<0.005) 
mean concentration compared to wt cells (194 pmol/106 cells). This suggests that 
differential TPMT expression influenced the intracellular concentrations of both 6-










Figure 2.7: Intracellular metabolite concentrations in 6-MP and 6-TG treated 
cells. (a) 6-TGN concentration in cells after 6-MP treatment. (b) 6-TGN levels after 6-TG 
treatment. (c) 6-MeMP metabolite concentrations in 6-MP treated cells. Data represent mean 





Thiopurines in addition to having good clinical efficacy demonstrate wide inter-
individual variability in terms of response.5 This inter-individual variability, resulting 
from differences in thiopurine metabolism, can cause adverse drug reactions or 
treatment resistance in patients.22,94,95 The side effects and resistance to thiopurines 
have been partly attributed to variable accumulation of thiopurine metabolites. The 
major determinant of these metabolite concentrations is TPMT.96 During thiopurine 
metabolism, TPMT catalyzes the S-methylation of these aromatic and heterocyclic 
sulfhydryl compounds which converts the drugs into inactive metabolites. Human 
TPMT activity is inherited as an autosomal codominant trait. There are many known 
single nucleotide polymorphisms that can cause a reduction in TPMT activity. 
Patients with reduced TPMT activity will require a much lower dose of the drug to 
avoid toxicity from excess active metabolites.21  
In these studies, we established RNA interference based TPMT knockdown in Jurkat 
T lymphocytes to demonstrate the contribution of TPMT expression to some 
pharmacological effects of thiopurines.  We employed SiDE guidelines 97 for specific 
and accurate shRNA design. Initial transfection experiments in CCRF-CEM cells 
demonstrated different efficiencies of four shRNAs tested. shRNAs with a 29mer 
stem and 2 nucleotides 3´ overhang  were more potent inducers of RNA 
interference.93 Therefore two sets of shRNAs one with minimum and the other 
showing maximum TPMT transcript degradation were selected for modification at the 
stem. Elongation of stems to 29mer improved the potency of both shRNAs. Greater 
efficiency of the 29mer shRNAs reflects the efficient entry of these RNAs into RNAi 
pathway as natural intermediates.98 shRNA4 was selected for further transfection and 
selection of clones in Jurkat T lymphocytes. Different clones were picked and tested, 
clone 9 (Jurkat kd) with the lowest TPMT expression was selected for further 
experiments. TPMT stable knockdown was verified at the mRNA, protein, and 
functional levels. Real time PCR and Western blotting results correlated and 
demonstrated significant and stable decrease in TPMT expression.  
Thiopurine methyltransferase status can be assessed either by measuring enzyme 
activity directly in circulating red cells (phenotype), or by genotyping in leukocytes.99 
TPMT activity is generally defined as the formation of 1 nmol of metabolite e.g. 6-
MPor 6-MeTG (6-methylthioguanine) per milliliter of packed red blood cells per hour 
36 
 
incubation at body temperature (37°C).21 In the human population high, intermediate 
and low TPMT activities have been described.100,101  However, TPMT activity is 
highly method dependent.102 In our study TPMT activity of Jurkat wt and kd cells was 
6.1 IU and 1.7 IU (normalized to microgram protein). Low TPMT activity of the Jurkat 
wt cells might be due to differences in sample type and methods of normalization of 
enzyme activity. TPMT activity is  usually measured in pRBC and expressed as 
IU/mL pRBC.103 In this study using cultured lymphocytes, enzyme activity was 
normalized to protein content instead. 
 
Pharmacokinetic and pharmacodynamic studies in CCRF-CEM cells and embryonic 
kidney cells indicated that elevation in TPMT activity rendered the cells less sensitive 
to 6-TG but more sensitive to 6-MP.23 Jurkat wt and kd cells also showed different 
levels of sensitivity to 6-MP and 6-TG. At maximum 6-MP (10 µmol/L) and 6-TG (8 
µmol/L) concentrations kd cells were more sensitive than wild type cells. This finding 
is in line with the known role of thiopurine inactivation by TPMT.104 In kd cells low 
TPMT expression caused less methylation of 6-MP and 6-TG which resulted in more 
6-TGN formation. Both cell types were more sensitive to 6-TG than to 6-MP. This 
might be due to the relatively direct conversion of 6-TG into its active metabolite 6-
TGN by avoiding many rate limiting enzymatic steps.105 In previously described 
TPMT models, variable contribution of TPMT towards the toxicity of 6-MP and 6-TG 
has been reported.82 Different levels of TPMT activity might not affect 6-MP and 6-TG 
similarly. In our model TPMT status affected 6-TG toxicity more than 6-MP. 
Comparing IC60 data for 6-MP and 6-TG, no significant difference was observed in 6-
MP toxicity in wt versus kd cells. But, in the Jurkat kd cells, 6-TG IC60 was much 
lower than in wt cells. 
The immunosuppressive effects of thiopurines are the result of a balanced 
contribution of pro-apoptotic and antimetabolite effects via 6-TGN and methylated 
ribonucleotides, respectively.106 Thiopurines induce apoptosis by incorporating in 
DNA and RNA or by modulation of Rac1 activation upon CD28 costimulation.107  
Significant caspase-3 activity was induced by 6-MP and 6-TG, confirming the pro-
apoptotic effects of these thiopurines. However, the IC60 of 6-TG in kd cells was 
considerably lower than in wt cells. Jurkat kd cells had levels of caspase-3 activity 
that were similar to wt cells after 6-TG treatment, suggesting increased efficacy of 
this drug as a result of TPMT knockdown.  
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TPMT is a key enzyme whose activity determines the levels of 6-MeMP as well as 6-
TGN metabolites.74 TPMT methylates 6-MP (to produce 6-MeMP) and 6-TIMP (to 
produce the 6-methylmercaptopurine ribonucleotide (MMPR)).108 Elevated 
concentrations of 6-MeMP (> 5700 pmol/8x108 erythrocytes)  are reported to be 
associated with a higher risk for hepatotoxicity109; however there are also 
contradictory reports where no correlation was found. 110 6-TGN metabolites are 
responsible for the therapeutic activity of thiopurines.109 Determining TPMT status 
along with monitoring metabolite concentrations (i.e. 6-TGN) is a suggested strategy 
for improving therapeutic  outcomes.111 We measured accumulated 6-TGN and 6-
MeMP bases after treatment with 6-MP and 6-TG. These metabolite concentrations 
correlated with the different levels of sensitivity seen between wt and kd cells.  6-TGN 
effects were not much different in wt and kd cells, and similar concentrations were 
achieved with 6-MP and 6-TG. Similar 6-TGN concentrations might be the result of 
using equitoxic amounts of 6-MP and 6-TG. The concentration of 6-MeMP depends 
on the amount of methylation of 6-MP by TPMT.108 In kd cells, reduced expression of 
TPMT resulted in very low methylation of 6-MP, hence 6-MeMP concentrations were 
negligible in kd cells. 
 
2.6 Conclusion 
In conclusion, we have for the first time established a TPMT knockdown cell culture 
model that is analogous to human TPMT deficiency polymorphism. We have tested 
enzyme activity, sensitivity to drugs, the proapoptotic effects of thiopurines, and 
accumulation of metabolites in this model. The results suggest that TPMT affects 6-
MP and 6-TG differently. Increased sensitivity of Jurkat kd cells to thiopurines 
correlates well with the therapy related myelosuppression observed in TPMT 
deficient patients. These cells could serve as useful in vitro model for a variety of 
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Thiopurines are extensively used as immunosuppressive and anti-leukemic drugs. 
Polymorphism of thiopurine S-methyltransferase (TPMT) influences thiopurine 
metabolism and therapy outcome. Little is known about the influence of thiopurine 
therapy on the proteome and phosphoproteome of cells having different TPMT 
activity levels. We used a newly established TPMT knockdown model of human 
Jurkat T-lymphocytes cells (kd) to study the effects of treatment with 6-
mercaptopurine (6-MP) and 6-thioguanine (6-TG). We employed proteomics 
approach to identify and compare the effects of this treatment on proteomes and 
phosphoproteomes of Jurkat cells with wild type (wt) and kd TPMT expression. We 
identified thirteen proteins with altered expression; six were differentially regulated in 
Jurkat kd cells compared to wt. 6-MP and 6-TG treatment regulated the expression of 
three proteins in kd cells compared to respective controls, while nine proteins were 
regulated in wt cells. In addition, nine proteins were identified with altered 
phosphorylation signal in different groups. Four proteins [thioredoxin, thioredoxin 
domain containing protein 17, glutathione S-transferase Mu 3 and thioredoxin-
dependent peroxide reductase] with putative functions in cellular oxidative stress 
response were regulated by 6-MP and 6-TG treatment. Furthermore, the reactive 
oxygen species assays confirmed a significant induction of oxidative stress by TPMT 
knockdown, 6-MP and 6-TG treatment. We observed that thiopurine treatment of 
human cells with differential TPMT expression can affect important DNA damage 
response and oxidative stress targets. Further characterization of these targets may 
help to understand the complex relationships between metabolism and mechanisms 
of action of thiopurines in patients with TPMT polymorphisms. 
 









Thiopurines [e.g. azathioprine (AZA), 6-mercaptopurine (6-MP) and 6-thioguanine (6-
TG)] are purine analogues that induce immunosuppression and reduce proliferation 
of cancerous cells.112 Different thiopurine mechanisms of action have been reported 
that include blocking replication by incorporation into DNA and transcription by 
incorporation into RNA, blocking Rac-1-mediated signal transduction, and an 
antimetabolic effect through inhibition of GTP synthesis by 6-methyl thioinosine 
monophosphate (6-MeTIMP).113 
 
Thiopurines are pro-drugs which undergo extensive metabolism in order to exert their 
cytotoxic action.11 The complex metabolism of these agents has been investigated 
extensively in an attempt to elucidate their mechanisms of action for efficacy and 
toxicity.11 There are three competing thiopurine metabolic pathways i.e. conversion to 
6-thioguanine nucleotides (6-TGN) by hypoxanthine guanine phosphoribosyl 
transferase (HPRT), inosine monophosphate dehydrogenase (IMPDH) and various 
kinases and reductases; methylation by the polymorphic enzyme, thiopurine S-
methyltransferase (TPMT); and catabolism to thiouric acid by xanthine oxidase 
(XO).114 
 
TPMT catalyzes the S-methylation of thiopurine drugs and exhibits a trimodal 
distribution of enzyme levels in erythrocytes.115 The TPMT gene polymorphism leads 
to an almost 50-fold variation in enzyme activity between individuals.116 Variations in 
response to thiopurine drug therapy are mainly caused by TPMT genetic 
polymorphism.115 Adverse effects of 6-MP/AZA, include bone marrow suppression 
which is of major concern, occurring in 2–5% of inflammatory bowel disease (IBD) 
patients treated with thiopurines.117 Risk of thiopurine induced myelosuppression is 
increased in patients with TPMT deficiency, which occurs in 0.3% (homozygosity, low 
or absent levels) to 11% (heterozygosity, intermediate levels) of the general 
population.118 
 
Thiopurines are known to induce oxidative stress especially in mitochondria119 
resulting in mitochondrial dysfunction and activation of stress activated protein kinase 
pathways.120 AZA induced oxidative stress causes tricarboxylic acid cycle dysfunction 
by depleting crucial mitochondrial enzymes.121 6-TGN is also known to incorporate 
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into mitochondrial DNA (mtDNA) where it is rapidly oxidized and inhibits mtDNA 
replication which leads to decreased mitochondrial protein concentrations and loss of 
mitochondrial function.122 Gene expression studies have also reported alterations in 
the expression of genes involved in protein and ATP-biosynthesis induced by 
thiopurine treatment.34 When mice were treated with 6-MP, significant expression 
alterations were observed in genes associated with abnormal lipid metabolism, 
inflammatory responses, oxidative stress, ATP depletion and cell death.33 
 
In the study reported here we employed a proteomic approach to identify cellular 
targets of thiopurine therapy associated with differential TPMT activity. Human TPMT 
knockdown cells123 were used for the first time as a model in a proteomic profiling 
study. Functional association of regulated proteins might be helpful in understanding 
the influence of thiopurine therapy on crucial cellular processes or indentify new 
cellular targets or potential approaches to individualized therapy with thiopurine 
drugs. 
 
3.3 Material and methods 
 
3.3.1 Reagents 
All cell culture reagents, RPMI, fetal calf serum (FCS), phosphate buffered saline 
(PBS), penicillin and streptomycin were purchased from PAA Laboratories, Colbe, 
Germany. Acetonitril (ACN) was purchased from Promochem, Wasel, Germany. 
CHAPS was obtained from Appli-Chem, Darmstadt, Germany. Urea, thiourea, 
dithiothreitol (DTT), trypsin, trifluoroacetic acid (TFA), sodium carbonate, ammonium 
bicarbonate, 6-MP, 6-TG and DMSO were obtained from Sigma-Aldrich, Steinheim, 
Germany. Ampholytes, protein assay kits and immobilized pH gradient strips (IPG 
strips) were obtained from Bio-Rad, Munich, Germany. Protease and phosphatase 
inhibitor cocktails were procured from Roche, Mannheim, Germany. Glycerin, 
potassium ferricyanide and sodium thiosulfate were purchased from Merck, 
Darmstadt, Germany.Formic acid was from BASF, Ludwigshafen, Germany. 
Bromophenol blue and trizma base were from Carl Roth, Karlsruhe, Germany. 
Sodium dodecyl sulfate (SDS) was purchased from Serva, Heidelberg, Germany.  
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3.3.2 Cell cultures 
The Jurkat cell line was obtained from the German Collection of Microorganisms and 
Cell Cultures (DSMZ), Braunschweig, Germany. Cells were maintained in RPMI 
supplemented with 10% (v/v) heat-inactivated FCS, 100 U/mL penicillin and   0.1 
mg/mL streptomycin at 37°C in 95% humidity, 20% O2 and 5% CO2 in 75 cm
2 culture 
flasks (Sarstedt, Nuembrecht, Germany). Jurkat knockdown (kd) cells were 
maintained under hygromycin (Cayla, France) selective pressure (200 µg/mL).  
 
3.3.3 Sample preparation for proteome analysis 
Jurkat wt and kd cells were treated for 48 h with DMSO or IC60 doses of 6-MP (4.6 
μmol/L and 4.7 μmol/L for wt and kd, respectively) or 6-TG (2.7 μmol/L and 0.8 
μmol/L for wt and kd, respectively). Cells were harvested and washed three times 
with ice cold PBS. Washed cells were pelleted down at 1800 rpm for 10 min at 4°C 
and lysed in a buffer containing 7 mol/L urea, 2 mol/L thiourea, 4% w/v CHAPS, 2% 
ampholyte [pH 3-10] and 1% DTT. The protein content of lysates was estimated by 
Bradford assay124 using Bio-Rad protein reagent according to manufacturer‟s 




The 2-DE was performed as described previously 125 with some minor modifications. 
Briefly, protein samples (130 μg) of Jurkat wt and kd cells were mixed with 
rehydration buffer (7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 0.2% ampholyte [pH 
3-10], and 0.2% DTT) containing a trace amount of bromophenol blue to a total 
volume of 330 μL. For rehydration (passive) samples were applied to non-linear IPG 
strips [pH 3-10] for 1 h then covered with mineral oil and allowed to stand overnight at 
room temperature. Iso-electric focusing (IEF) was performed in a Protean IEF cell 
(Bio-Rad) with the following configuration: 1 h at 100 volts, 1 h at 500 volts, 2 h at 
1000 volts and 8000 volts with a total of 32000 volts-h. Before the second dimension 
electrophoretic separation, focused IPG strips were equilibrated for 30 min at room 
temperature in a buffer containing 50 mmol/L Tris-HCL [pH 8.8], 6 mol/L urea, 30% 
v/v glycerol, 2% SDS and 10 g/L DTT followed by incubation in identical buffer in 
which DTT was replaced with 40 g/L iodoacetamide. The proteins in the equilibrated 
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strips were then resolved on the 12.5% SDS-PAGE in a Protean II chamber (Bio-
Rad) at 100 V and 4°C.  
3.3.5 Phospho-specific staining of 2-DE gels 
 
Gel fixation was performed twice in a solution containing 50% methanol and 10% 
acetic acid for 45 minutes each followed by three 15 min washes in double distilled 
water. Gels were stained with Pro-Q Diamond phospho stain (Invitrogen, Paisley, 
UK) overnight in the dark at room temperature, destaining was done three times for 
30 min in destaining solution containing 20% ACN and 50 mmol/L sodium acetate, 
followed by three washes in double distilled water each for 5 min. Gels were scanned 
using an imaging instrument (FLA-5100 Fuji photo film, Dusseldorf, Germany) at a 
wavelength of 532 nm.  
 
 
3.3.6 Protein visualization, densitometric analysis  
 
Gel staining (silver) was performed as described by Blum et al 1987.126 Briefly, gels 
were fixed, followed by washing and sensitization. The gels were stained with freshly 
prepared silver nitrate solution (0.2% silver nitrate and 0.026% formaldehyde) for 20 
min at room temperature followed by three 20 sec washes in double distilled water. 
Gels were immersed in developing solution containing 6% sodium carbonate, 
0.0185% formaldehyde and 6% sodium thiosulfate. When spots appeared, the 
reaction was stopped with stop solution (50% methanol and 12% acetic acid). After 
developing, gels were scanned with a color image scanner Cano scan 8400 (Canon, 
Tokyo, Japan). Five independent 2-DE experiments were performed with each 
treatment and cell type. Densitometric analysis of protein spots was performed using 
Delta 2D software version 3.6 (Decodon GmbH, Gerifswald, Germany).127 Spot 
intensities were normalized by dividing the intensity of each spot by the sum of all 
spots‟ intensities on the corresponding gel and the resultant intensity was considered 
as the relative intensity of that spot. Spots showing at least 1.5 fold expression 





3.3.7 Tryptic digestion 
Differentially expressed spots were excised from silver stained gels, followed by in-
gel digestion according to the modified method earlier described by Shevchenko and 
colleagues.128 Briefly, excised gel spots were washed with 30 mmol/L potassium 
ferricyanide and 100 mmol/L sodium thiosulfate for destaining; followed by washing 
with 50% ACN and 100 mmol/L ammonium bicarbonate, and drying in a vacuum 
centrifuge (UNIVAPO, uniEquip, Martinsried, Germany). After drying, tryptic digestion 
was performed with trypsin digestion buffer (0.1 μg/μL trypsin, 1 mol/L calcium 
chloride, and 1 mol/L ammonium bicarbonate) on ice for 45 min and then incubated 
overnight in digestion buffer without trypsin at 37°C. The peptides were extracted 
with increasing concentrations of ACN and TFA and the extracted peptides were 
dried by vacuum centrifugation. Peptides were reconstituted in 0.1% FA for injecting 
into a nano-flow HPLC. 
 
 
3.3.8 Peptide sequence analysis using nano LC ESI Q-TOF MS/MS 
and database search 
 
Peptide samples (1 μl) were introduced onto two consecutive C18-reversed phase 
chromatography columns (C18 pepMap: 300 μm × 5 mm; 5 μm particle size, and 
C18 pepMap100 nanoanalytical column: 75 μm × 15 cm; 3 μm particle size; LC 
Packings, Germering, Germany) using a nano-flow CapLC autosampler (Waters, 
Eschborn, Germany). Peptides were eluted with an increasing gradient of ACN and 
analyzed on a Q-TOF Ultima Global mass spectrometer (Micromass, Manchester, 
UK) equipped with a nanoflow ESI Z-spray source in the positive ion mode, as 
previously described.129 The data were analyzed with the MassLynx (version 4.0) 
software. The peaklists were searched using the online MASCOT search engine 
(http://www.matrixscience.com) against the UniProt/SwissProt database release 
15.15 (515203 entries, 181334896 elements). The data were searched against the 
database using the following parameters: trypsin as enzyme for digestion; up to a 
maximum of one missed cleavage site allowed; monoisotopic mass value and with 
unrestricted protein mass; peptide tolerance ± 0.5 Da and MS/MS tolerance ± 0.5 Da. 
Proteins were identified on the basis of two or more peptides, whose ions score 
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exceeded the threshold and p ≤ 0.05 reflects the 95% confidence level for the 
matched peptides. 
3.3.9 Functional classification 





3.3.10 Western blotting 
Western blotting was performed as previously described 131. Briefly, proteins were 
separated on 12.5% SDS-PAGE and blotted onto PVDF membrane (Millipore, 
Schwalbach, Germany) using a semi-dry transblot system (SD transblot, Bio-Rad, 
Munich, Germany). The membrane was blocked with 5% skimmed milk powder 
prepared in TBS-T buffer (50 mmol/L Tris-HCl [pH 7.5], 200 mmol/L NaCl, and 0.05% 
Tween 20) for one hour at room temperature. After washing three times with TBS-T 
buffer, the membrane was incubated with 1:1000 rabbit anti-stathmin (Cell Signaling 
Technology, Danvers, MA) and 1:10000 mouse beta-actin (Sigma-Aldrich, Steinheim, 
Germany) overnight at 4°C. After completion of incubation the membrane was 
washed and further incubated with appropriate HRP-conjugated secondary 
antibodies for 1 h at room temperature. Proteins were detected using an enhanced 
chemiluminescent (ECL) reagent (GE Healthcare, Munich, Germany). Blots were 
developed on Amersham Hyperfilm (GE Healthcare, Munich, Germany). Four 
independent experiments were performed and signal intensities from each 




3.3.11 ROS assay 
The level of reactive oxygen species was determined as described previously 132 with 
some modifications. After treatment of cells with IC60 doses of 6-MP and 6-TG for   
48 h, media was removed by centrifugation. Cells were resuspended in PBS 
containing 10 μmol/L DCFDA (Sigma-Aldrich, Steinheim, Germany) and incubated at 
37°C for one hour. The fluorescence intensity was determined with a Lambda Fluoro 
320 fluorescence plate reader (MWG Biotech, Panzberg, Germany) with the 
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excitation and emission wavelength settings at 485 and 530 nm, respectively. Finally, 
cell counting was done for each sample for normalization. ROS assay was repeated 
in four independent cell preparations, each in a triplicate format.  
3.4 Results 
The influence of thiopurine treatment on the proteome and phosphoproteome of 
human T-lymphocytes (Jurkat) with wild type (wt) TPMT expression and knockdown 
(kd) cells with reduced TPMT expression was investigated. Cells were treated with 
vehicle DMSO or IC60 doses of 6-MP or 6-TG for 48 h. After treatment cells were 
harvested, lysed and total protein lysate was used for 2-DE. The gels were stained 
with phospho specific staining followed by silver staining. Differentially regulated 
spots with ≥ ± 1.5 fold changes (p ≤ 0.05 as determined by student´s t test) were 
excised, digested and identified by Q-TOF MS/MS analysis. Statistical analysis 
showed that a total of thirteen proteins showed significant altered expression and 
nine proteins showed altered phosphorylation (Fig. 3.1) Predicted and actual pI of 
proteins, as well as molecular masses with their SwissProt accession numbers, and 








Figure 3.1: Schematic representation of experimental system (a) Silver stained    
2-DE gel (Jurkat wt DMSO), (b) Phospho stained 2-DE gel (Jurkat wt DMSO), (c) 
Jurkat wt and kd cells were treated with IC60 doses of 6-MP, 6-TG, and vehicle (DMSO) for 
48 h. Total protein lysates from DMSO, 6-MP and 6-TG treated Jurkat wt and kd cells were 
separated by 2-DE and silver stained. Consistently regulated (circled) spots were identified 
by Q-TOF MS/MS analysis. Densitometric analysis of Jurkat wt and kd groups (a), DMSO 




















3.4.1 Proteins regulated by TPMT knockdown 
Comparison of Jurkat kd cells grown in DMSO, 6-MP or 6-TG to their wt counterparts 
showed altered expression of six proteins in kd cells (Fig. 3.1b, Table 3.I). Among 
these proteins four were significantly up-regulated (spots 2-5) and two were down-
regulated (spots 1 & 13). Heterogenous ribonucleoprotein H3 (HNRH3), delta (3, 5)-
delta (2, 4)-dienoyl-CoA isomerase (ECH1), deoxyuridine 5‟-triphosphate 
nucleotidohydrolase, mitochondrial (DUT) and cofilin1 (COF1) were up-regulated. 
Ataxin10 (ATX10, spot 1) was down-regulated in kd DMSO cells compared to wt 
DMSO. Myotrophin (MTPN, spot 13) was down-regulated in kd 6-TG cells compared 
to wt 6-TG. Figure 3.2a shows differentially expressed COF1 spot in all six treatment 
groups. Densitometric analysis of phospho stained gels showed six proteins with 
altered phosphorylation signal (Table 3.2, Fig. 3.1c shows a representative phospho 
stained gel of wt DMSO with these spots marked). Four proteins exhibited increased 
phosphorylation as a result of knockdown [i.e.  6- phosphofructokinase type C (K6PP, 
spot 1), T-complex protein 1 subunit zeta (TCPZ, spot 2), glutathione S-transferase 
Mu 3 (GSTM3, spot 8) and thioredoxin-dependent peroxide reductase (PRDX3, spot 
9)]. Rab GDP dissociation inhibitor beta (GDIB, spot 4) and mRNA export factor 
(RAE1L, spot 7) showed decreased phosphorylation in kd cells. Figure 3.2b shows 
the differentially phosphorylated protein spot of PRDX3 seen in all six groups.  
Some important targets of cellular oxidative stress response were identified: THIO, 
TXD17, GSTM3 and PRDX3. Proteins involved in cytoskeleton are also sensitive to 
oxidative stress and we observed regulation of important proteins of cytoskeletal 
machinery i.e. COF1 and PROF1 in wt and knockdown cells. As a result of these 
findings, we determined cellular oxidative stress using the ROS assay (Fig. 3.6a-e). 
Intensity of fluorescence generated by incubating treated and control cells with the 
fluorescence dye DCFDA was measured and normalized to total cell number in each 
sample. Results showed significantly increased fluorescence intensity in wt and kd 







Figure 3.2: Differential expression of COF1 (a) and differential phosphorylation 
of PRDX3 (b).COF1 spot in all six groups showing significant differential expression in kd 
DMSO and wt 6-TG groups and non-significant difference in the other four groups (a). 
PRDX3 spot in all six groups showing significant differential phosphorylation in kd DMSO and 
kd 6-MP groups and non-significant difference in the other four groups (b). Graphical 
representation of spot density (% volume) with mean ± SD of five independent experiments 
(**p ≤ 0.005). 
 
3.4.2 Proteins regulated by 6-MP and 6-TG treatment in Jurkat wt 
cells 
Jurkat wt cells were treated with IC60 doses of 6-MP (4.6 µmol/L) and 6-TG (2.8 
µmol/L). Comparison of 6-MP treated cells with their DMSO controls showed 
significant expression changes in three proteins (Table 3.I). Spot 6, corresponding to 
stathmin1 (STMN1), was down-regulated (Fig. 3.4a). Regulation of STMN1 was 
further confirmed by Western blot analysis (Fig. 3.4b). Spot 7, identified as costars 
family protein ABRACL (ABRAL), was also significantly down-regulated in wt 6-MP 
cells. Spot 11, haemoglobin subunit alpha (HBA), was up-regulated as a result of 6-
MP treatment in wt cells. 6-TG treatment influenced expression of seven proteins in 
wt cells. COF1, thioredoxin (THIO), profilin 1 (PROF1), macrophage migration 
inhibitory factor (MIF), hemoglobin subunit alpha (HBA), thioredoxin domain 
containing protein 17 (TXD17) and MTPN were up-regulated. These proteins 
corresponded to spots 5, 8-13 respectively and are marked in a representative gel 
(Fig. 3.1a). Figure 3.3a shows differentially expressed HBA in all six groups. 
Alteration of phosphoproteome was also observed after 6-MP and 6-TG treatment. 
Five proteins showed significantly changed phosphorylation signal; two in the 6-MP 
and three in the 6-TG group (Table 3.2, Fig. 3.1c). Coronin-1A (COR1A) or spot 3 
showed significantly down-regulated phosphorylation in the wt 6-MP group. 
Deceased phosphorylation was observed in 26S protease regulatory subunit 10B 
(PRS10, spot 6). In the 6-TG group, actin related protein-2 (ARP2, spot 5), showed 
down-regulation of phosphorylation; while RAE1L (spot 7) and GSTM3 (spot 8), 
showed up-regulation of phosphorylation. Figure 3.3b shows the differentially 




Figure 3.3: Differential expression of HBA and differential phosphorylation of 
ARP2. HBA spot in all six groups showing significant differential expression in wt 6-MP, wt 
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6-TG and kd 6-TG and non-significant difference in the remaining three groups (a). ARP2 
spot in all six groups showing significant differential phosphorylation in wt 6-TG and non-
significant difference in the other five groups (b). Graphical representation of spot density (% 
volume) with mean ± SD of five independent experiments (**p ≤ 0.005). 
 
 3.4.3 Proteins regulated by 6-MP and 6-TG treatment in Jurkat kd 
cells  
Jurkat kd cells were treated with IC60 doses of 6-MP (4.7µmol/L) or 6-TG (0.8 
µmol/L). In total three proteins were differentially regulated, one in the 6-MP group 
and two in the 6-TG group (Table 3.1). STMN1 was down-regulated after 6-MP 
treatment (Fig. 3.4a, b). ECH1 was significantly up-regulated in the kd 6-TG group. 





Figure 3.4: Differential expression of STMN1 as shown by silver stained gels (a) 
and Western blot analysis (b). (a) STMN1 spot in all six groups showing significant 
down regulation in wt and kd 6-MP treated groups. Graphical representation of spot density 
(% volume) with mean ± SD of five independent experiments (*p ≤ 0.05). (b) Total protein 
lysates from DMSO or 6-MP or 6-TG treated Jurkat wt and kd cells were separated by 1-D 
gel electrophoresis and immunoblotted with antibody against STMN1. Densitometric 
analyses were performed using Lab Image 2.71 software. Beta-actin was used as a loading 
control. The error bars represent mean ± SD of four independent experiments (*p ≤ 0.05). 
 
Quantitative analysis showed four proteins with altered phosphorylation; one in the 6-
MP and three in the 6-TG group (Table 3.2). In the kd 6-MP group TCPZ showed 
increased phosphorylation compared to the DMSO control (Fig. 3.5). In the kd 6-TG 
group K6PP showed decreased phosphorylation, while RAE1L and GSTM3 showed 
increased phosphorylation as a result of 6-TG treatment. Figure 3.1c shows a 





Figure 3.5: Differential phosphorylation of TCPZ. TCPZ spot in all six groups 
showing significant differential phosphorylation in the kd 6-MP treated group. Graphical 
representation of spot density (% volume) with mean ± SD of five independent experiments 





Figure 3.6: ROS assay after 6-MP and 6-TG treatment. Cells were treated with 
vehicle DMSO or IC60 doses of 6-MP or 6-TG for 48 h. After treatment media was removed 
the cells were resuspended in PBS containing 10 µM DCFDA. Fluorescence intensity was 
measured after 1 h incubation at 37°C. Comparison of fluorescence intensity in Jurkat wt 
group (a) Jurkat kd group (b) Jurkat kd vs wt group DMSO (c) 6-MP (d) 6-TG (e). The error 
bars represent mean ± SD of four independent experiments (in triplicate format each), *p ≤ 
0.05, ***p ≤ 0.0005. 
 
3.5 Discussion 
We employed a 2-DE and mass spectrometric approach to study the influence of 
thiopurine therapy and differential TPMT activity on proteome and phosphoproteome 
of Jurkat T-lymphocytes. In our study, we observed significant changes at the 
proteome and phosphoproteome level, as a result of TPMT knockdown and 
thiopurine treatment. The proteins with significant altered expression and 
phosphorylation identified in this study are involved in diverse cellular functions 
including homeostasis, cell cycle regulation, DNA damage response, apoptosis, 
cytoskeleton dynamics, energy metabolism, oxidative stress response etc (Table I). 
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3.5.1 Proteins regulated by TPMT knockdown 
TPMT knockdown resulted in altered expression of six proteins i.e. ATX10, HNRH3, 
ECH1, DUT, COF1 and MTPN. ATX10 which is responsible for Spino cerebellar 
ataxia (SCA) type 10 133 was down-regulated as a result of TPMT knockdown. The 
hnRNPs are multifunctional proteins; they participate in pre-mRNA splicing, export, 
localization, translation and stability.134 HNRH3 is an hnRNP; its increased 
expression indicates a possible effect of TPMT knockdown on mRNA synthesis and 
processing. ECH1, which was up-regulated in kd 6-TG exposed cells is a rate limiting 
enzyme in mitochondrial ß-oxidation.135 DUT is one of the enzymes which recognize 
and remove uracil moieties from DNA.136 Up-regulation of DUT was observed in 
Jurkat kd (DMSO and 6-TG exposed cells). Increased expression of two 
mitochondrial enzymes (i.e. ECH1 and DUT) as a result of knockdown might also 
indicate involvement of TPMT in mitochondrial processes. COF1, a key player in 
actin dynamics and an emerging agent of cellular homeostasis 137, was up-regulated 
in kd (DMSO, 6-MP and 6-TG) cells, indicating importance of TPMT in cellular 
homeostatic processes. MTPN is an ankyrin repeat protein which is ubiquitously 
expressed in all mammalian tissues.138  MTPN is a multifunction protein 138  whose 
expression was down-regulated in the kd 6-TG group. COF1 and MTPN are involved 
in actin dynamics and polymerization, respectively. Their altered expression in kd 
cells might indicate possible involvement of TPMT or its substrates in cytoskeleton 
regulation. Results also showed altered phosphorylation of six proteins K6PP, TCPZ, 
GDIB, RAE1L, GSTM3 and PRDX3. K6PP is a 6-phosphofructo-1-kinase (PFK-1); 
these kinases are one of the key regulatory enzymes in the glycolytic pathway.139 
K6PP activity may be regulated by phosphorylation/dephosphorylation.
140 Studies on salivary glands, reported that phosphorylation of PFK-1 has dual 
activation. Initially enzyme is activated by an increased phosphorylation state but a 
higher state of phosphorylation inhibits the enzyme activity.141 TCPZ is a subunit of 
chaperonin containing TCP-1 (CCT) which is involved in the production of native 
actin, tubulin and numerous other proteins required for cell cycle progression.142 We 
observed increased phosphorylation of TCPZ in kd 6-MP compared to wt 6-MP. 
Altered phosphorylation of this TCPZ subunit possibly indicates change in affinity of 
CCT towards substrate proteins as result of knockdown and 6-MP treatment. Rab 
GDP dissociation inhibitors bind prenylated Rab-GTPases, deliver Rab proteins to 
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specific compartments, and retrieve Rabs from fusion targets after completion of the 
catalytic cycle.143 TPMT knockdown decreased phosphorylation of GDIB. Previous 
studies showed that phosphorylated GDI might be more effective in retrieving Rab 
proteins from membranes.144 Decreased GDIB phosphorylation might indicate 
alteration in GDIB activity which could consequently modulate cell cycle progression. 
RAE1L is a shuttling transport factor that permits efficient export of mRNA 
through the nuclear pore complex (NPC).145 During cell cycle transitions NPC 
dynamics play a critical role.146  Phosphorylation of RAE1L and some other proteins 
of the nuclear complex by mitotic kinases results in altered NPC dynamics.147 RAE1L 
phosphorylation was increased as a result of 6-TG treatment, but compared to wt 6-
TG its signal was weaker. GSTM3 is a member of the Glutathione S-transferase 
(GST) family; it protects cells from oxidative stress by neutralizing reactive 
compounds.148 Post-translational modifications such as serine, thereonine or tyrosine 
phosphorylation can modulate GST stability and function.149 GST was previously 
known for its role in conjugation of AZA with glutathione, a step required for its 
conversion to 6-MP. A correlation between GST polymorphism and AZA adverse 
effects is also known.150 In this study, 6-TG treatment caused increased GSTM3 
phosphorylation. PRDX3 (thioredoxin peroxidase-2), localized in mitochondria, uses 
mitochondrial thioredoxin-2 (Trx2) as the electron donor to scavenge H2O2. PRDX3 
phosphorylation is associated with decreased peroxidase activity, increased oxidative 
stress, and consequently dysregulation in mitochondrial function.151 Increased 
GSTM3 and PRDX3 phosphorylation in TPMT kd cells also correlates with the 
oxidative stress observed in the ROS assay results. In kd cells oxidative stress was 
significantly higher compared to wt cells, with and without treatment. Since the 
natural substrate of TPMT is not known, it can be hypothesized that TPMT 
knockdown might affect metabolism of some endogenous compound(s) which could 




3.5.2 Proteins regulated by 6-MP and 6-TG treatment in Jurkat wt 
cells 
In Jurkat wt cells treated with 6-MP and 6-TG; comparison of proteome and 
phosphoproteome with DMSO controls demonstrated significant alterations. 6-TG 
affected expression of seven proteins i.e. COF1, THIO, PROF1, MIF, HBA, TXD17 
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and MTPN. STMN1 is a phosphoprotein which acts as a microtubule regulator during 
mitosis.152 6-MP treatment induced down-regulation of STMN1 also confirmed by 
immunoblot analysis. Inhibition of STMN1 expression is associated with severe 
mitotic spindle abnormalities and difficulty in the exit from mitosis that leads to the 
accumulation of cells in the G2/M phases.152 These results are consistent with 
previously known G2/M phase cell arrest caused by thiopurines.24  The known 
mechanism for this cell cycle arrest is DNA strand breaks.24 However, down-
regulation of STMN1 might also be a mechanism of G2/M phase arrest caused by 
thiopurines. ABRAL, a member of the costars family was down-regulated by 
exposure to 6-MP. There is not much functional information available for ABRAL (or 
HSPC280), but some studies indicate that it has a possible role in cell cycle 
regulation and DNA damage response.153,154 COF1 has a pro-apoptotic role; 
mitochondrial translocation of COF1 induces cytochrome c release and apoptosis.155 
ROS species also influence COF1 activity by promoting its dephosphorylation.156 
Hence, COF1 has also its role in oxidative stress induced cytoskeletal changes.156 
THIO catalyzes reversible reduction of protein disulfide bonds.157 It is primarily 
localized in the cytosol but with oxidative stress it translocates to the nucleus.157 
THIO up-regulation may be a response of 6-TG induced oxidative stress. Up-
regulation of COF1 and THIO might be the result of ROS generation after 6-TG 
exposure, which was demonstrated by use of the ROS assay. PROF1 is a small G-
actin binding protein which promotes actin polymerization in cells.158 PROF1 over 
expression induces cell cycle arrest in breast cancer cells and sensitizes cells to 
apoptosis in response to a cytotoxic stimulus.159 The PROF1 up-regulation observed 
here might also sensitized cells to 6-TG induced apoptosis. MIF was identified as a 
cytokine about forty years ago.160 More recently many other important functions of 
this cytokine other than in inflammatory conditions have been discovered including 
DNA damage response coordination 161, negative regulation of p53 mediated cell 
arrest 162, and anti-autophagic response.163 Alteration of expression of this 
multifunctional cytokine (MIF) by 6-TG possibly contributes to the complex 
mechanisms involved in the cytotoxicity of thiopurines. 
 
Altered intensity of the phosphorylation of five proteins was observed in wt cells. After 
6-MP exposure COR1A and PRS10 showed significant alterations of 
phosphorylation. Coronins influence actin dynamics by inhibiting Arp2/3 complex 
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nucleation.164 Studies on COR1B showed regulation of its interaction with Arp2/3 
through phosphorylation by protein kinase C (PKC).165 Eukaryotic cells regulate 
fundamental cellular processes by rapid destruction of key regulatory proteins, such 
as cell cycle regulators and transcription factors, catalyzed by PRS10.166 Studies on 
yeast showed decreased PRS10 ATPase activity after dephosphorylation and vice 
versa.167 In our study, decreased PRS10 phosphorylation was observed. This could 
have reduced PRS10 ATPase activity, inhibited its function, and thereby altered the 
cell cycle. This finding correlates well with thiopurine induced cell cycle disturbances. 
RAE1L and GSTM3 showed increased phosphorylation after 6-TG exposure. ARP2 
is related to actin and forms part of the Arp2/3 complex which controls actin 
dynamics.168 Phosphorylation of the Arp2/3 complex is necessary for actin filament 
nucleation. We observed down-regulation of ARP2 phosphorylation. This down-
regulation might have caused reduction in Arp2/3 complex activity and thereby 
affected actin dynamics. COR1A and ARP2 influence Arp2/3 nucleation and activity 
respectively. It can be hypothesized that thiopurine treatment might affect actin 
dynamics by manipulating Arp2/3 complex nucleation and activity.   
 
 
3.5.3 Proteins regulated by 6-MP and 6-TG treatment in Jurkat kd 
cells 
In kd cells 6-MP and 6-TG exposure affected expression of ECH1, STMN1 and MIF.  
ECH1 up-regulation might indicate drug effects on mitochondrial processes. Earlier 
studies have also showed effects of thiopurines on gene expression and 
mitochondrial function.121,122 Like wt, kd cells also showed down-regulation of STMN1 
after 6-MP. This finding indicates that 6-MP can affect STMN1 expression regardless 
of TPMT expression. 6-MP induced cell cycle disturbances might take place through 
the STMN1 pathway. MIF up-regulation was also found in both wt and kd 6-TG cells. 
Effects of thiopurine treatment on this important cytokine might indicate yet unknown 
aspects of thiopurine action. The phosphoproteome of kd cells was also significantly 
altered by 6-MP and 6-TG exposure but in different ways. TCPZ phosphorylation was 
increased by 6-MP while 6-TG decreased K6PP phosphorylation and increased 





This is the first study at the proteomic level of the effects of both thiopurine as well as 
differential TPMT activity. Proteins directly or indirectly involved in cellular responses 
to oxidative stress and DNA damage were significantly altered in all study groups. 
Similarly, significant influence on cell cycle regulation and cytoskeleton 
reorganization mechanism was observed. Taking together, these results suggest that 
thiopurine treatment can induce cytotoxicity by both DNA damage and increased 
oxidative stress. Cells respond to these stresses by regulating the expression and 
activity of important targets in the cell cycle and cytoskeleton systems. A significant 
effect on cytoskeleton machinery is also an indicator of the cellular response to 
stress. Although the exact mechanism of these alterations is not known, further 
investigation may help to understand the complex mechanisms of action of 























Thiopurines are purine analogues used as immunosuppressive and antileukemic 
agents in autoimmune diseases, leukemia and for prevention of organ transplant 
rejection. Thiopurine activation requires extensive metabolism that involves many 
enzymatic reactions and TPMT is one of the crucial enzymes in the thiopurine 
metabolic pathway. TPMT methylates 6-MP, 6-TG and their metabolites and through 
this methylation TPMT can significantly influence therapeutic outcomes. 6-TGN is the 
active metabolite of thiopurines that is mainly responsible for cellular cytotoxicity 
through its incorporation into DNA and RNA. Single nucleotide polymorphisms 
(SNPs) in the genes that control TPMT activity are responsible for variable TPMT 
enzyme activity. Most SNPs result in decreased expression and enzyme activity by 
exposing TPMT to increased proteasome mediated degradation. TPMT heterozygous 
and homozygous individuals have reduced or no detectable TPMT enzyme activity, 
respectively. In spite of intensive research on thiopurine metabolism and on the role 
of TPMT in therapeutic outcome a full understanding of these issues has not been 
achieved. 
The present study aimed to establish a TPMT stable knockdown model to serve as 
an in vitro model of TPMT deficiency, its characterization, and its use to understand 
the importance of TPMT SNPs in thiopurine therapy as well as the possible further 
exploitation of model for the identification of novel thiopurine cellular targets (Fig. 
4.1). Jurkat T-lymphocytes were transfected with pSi.2.1 containing TPMT specific 
shRNA. Transfected cells were then grown under selection pressure. A clone with 
maximum TPMT knockdown (kd) was selected and compared with and without 
exposure to thiopurines to non-transfected control cells (wt). Growth inhibition studies 
on wt and kd cells using 6-MP and 6-TG showed differential effects of TPMT 
expression. Jurkat kd cells were more sensitive to both 6-MP and 6-TG at maximum 
doses, but, the IC60 of 6-MP was not much different in wt and kd cells despite 
different methylation by TPMT. Contrary to results with 6-MP, TPMT kd cells were 
many fold more sensitive to 6-TG compared to wt cells as measured by their IC60 
doses.  
When a caspase-3 activity assay was performed after treating cells with IC60 doses of 
6-MP and 6-TG, a significant induction of apoptosis was observed in both cell types 
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by both drugs, confirming the pro-apoptotic effect of thiopurines. However, 
interestingly 6-TG treated kd cells showed the same level of caspase-3 activity as did 
the wt cells despite treatment with a considerably lower IC60 dose. This suggests that 
TPMT deficient cells are more sensitive to 6-TG induced apoptosis. This fact must be 
considered in patients treated with 6-TG. TPMT genotyping before commencing 
thiopurine therapy and a regular monitoring of metabolite levels along with blood 
counts during therapy is recommended. The accumulation of 6-MeMP and 6-TGN 
bases after treatment with 6-MP and 6-TG was also measured. These metabolite 
concentrations correlated with the different levels of sensitivity seen between wt and 
kd cells. 6-TGN concentrations achieved after 6-MP exposure was not much different 
between two cell types. However, significantly higher 6-TGN levels were found in kd 
cells than in wt cells. This finding clearly replicated the sensitivity of kd cells towards 
6-TG exposure. Collectively, kd cells had less methylation capacity for 6-TG and 
hence accumulated more active metabolite (i.e. 6-TGN) and as a result a higher 
apoptosis rate. 6-MeMP is representative of methylated metabolites and its 
concentration predicts the antimetabolite role of thiopurines. 6-MeMP concentrations 
were measured in 6-MP treated kd and wt cells. In kd cells, the 6-MeMP 
concentration was negligible, confirming successful knockdown and its significant 
effect on 6-MP metabolism.  
We further investigated novel cellular targets of thiopurine therapy using cells with 
different levels of TPMT expression (Fig. 4.2). We utilized a 2-DE mass spectrometric 
approach to examine effects on wt and kd cells treated with IC60 doses of 6-MP and 
6-TG.  Cells were harvested and cellular lysates were separated on 2-DE. Gels were 
stained with a phospho specific stain, followed by staining with silver for differential 
phospho and total proteome, respectively. Differentially regulated spots were 
identified by mass spectrometric analysis. A total of thirteen proteins showed altered 
expression and nine proteins showed altered phosphorylation in all groups. TPMT 
knockdown regulated expression of six proteins (i.e. ATX10, HNRH3, ECH1, DUT, 
COF1 and MTPN) and also altered the phosphorylation status of six proteins (i.e. 
K6PP, TCPZ, GDIB, RAE1L, GSTM3 and PRDX3). In wt cells treatment resulted in 
differential expression of nine proteins (i.e. STMN1, ABRAL, COF1, THIO, PROF1, 
MIF, HBA, TXD17 and MTPN).  The phospho proteome was also significantly 
affected by 6-MP and 6-TG treatment in wt cells. Five proteins (i.e. COR1A, PRS10, 
RAE1L, ARP2 and GSTM3) were identified with differential phosphorylation intensity. 
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Thiopurines also significantly affected the proteome (i.e. ECH1, STMN1 and MIF) 
and phosphoproteome (i.e. TCPZ, K6PP, RAE1L and PRDX3) of kd cells. Identified 
altered proteins fall into different functional categories; performing crucial roles in 
cellular homeostasis, cell cycle regulation, DNA damage response, apoptosis, 
cytoskeleton dynamics, energy metabolism and oxidative stress response. STMN1 is 
a microtubule regulating protein; its main function is timely entry and exit of cells from 
mitosis. Down-regulation of STMN1 was observed in 6-MP treated wt and kd cells 
which was further confirmed by Western blot analysis. STMN1 expression was 
regulated by 6-MP irrespective of TPMT status. Inhibition of STMN1 expression 
causes severe mitotic spindle abnormalities and accumulation of cells in the G2/M 
stage. This finding correlates with earlier reports of cell arrest at G2/M stage induced 
by thiopurines. Although the mechanism for this arrest is thought to be related to 
DNA strand breaks, STMN1 might also be responsible for this cell cycle arrest 
induced by thiopurines. Further investigation of this hypothesis may help to unravel 
the complex mechanism of action of thiopurines.  
Among the identified altered proteins, four proteins (i.e. THIO, TXD17, GSTM3 and 
PRDX3) are known to be involved in the oxidative stress response of cells. This 
observation indicated oxidative stress induction as a result of thiopurine treatment in 
the presence of knockdown. To confirm this, treated and untreated cells were 
exposed to ROS sensitive fluorescence dye (DCFDA) and levels of ROS species 
were determined. Significant increase in oxidative stress was observed in kd cells 
exposed to thiopurines confirming the proteome findings. Hence, we report for the 
first time the regulation of important oxidative stress related proteins by TPMT and 
thiopurines. 
In conclusion, we have developed a TPMT knockdown model which demonstrates all 
the characteristics of human TPMT deficiency that can serve as an in vitro model of 
TPMT polymorphism. Further investigations on these novel cellular targets 
associated with thiopurine exposure and TPMT activity can help to resolve the 





Figure 4.1: Influence of TPMT 
knockdown on TPMT activity and 6-
MP/6-TG treatment in Jurkat cells. 
TPMT knockdown in Jurkat cells caused 
decrease in TPMT expression and activity. 
TPMT kd cells when treated with IC60 doses 
of 6-MP and 6-TG, showed decreased 
inactivation of 6-MP compared to wild type 
cells. Furthermore, in comparison to wild 
type cells, TPMT knockdown cells were 
more sensitive to 6-TG treatment and 
exhibited higher level of apoptosis. Our 
results suggest that knockdown of TPMT in 
Jurkat cells was effective and influenced 6-
MP and 6-TG differently.  
 
Figure 4.2: Thiopurines induced 
oxidative stress and proteome 
regulation. 6-MP and 6-TG treatment 
induced phosphorylation changes in 
GSTM3 and PRDX3 (redox regulators of 
cell) which can consequently reduce their 
ROS neutralization activity.148,151 ROS assay 
showed an increase in ROS level after 6-
MP and 6-TG treatment. Increased ROS 
level may cause mitochondrial dysfunction 
169, persistent and increasing mitochondrial 
dysfunction could induce cellular 
cytotoxicity.170 On the other hand, to cope 
with increasing oxidative stress, cells could 
activate the cellular antioxidant mechanisms 
171 which are demonstrated by increased 
expression of THIO; an antioxidant 
protein.172  ROS accumulation also affect 
cytoskeleton 173, indicated by altered 
cytoskeleton regulator proteins (expression 
of COF1 and PROF1 and phosphorylation 
of p-ARP2, p-COR1A). 156,159,165,168 Oxidative 
stress influence cell cycle 174, and observed 
reduced expression of STMN1 (regulator of 
microtubule dynamics during meiosis) and decreased phosphorylation of PRS10 (involved in 
ATP dependent degradation of ubiquitinated proteins) may be indicative of the 
phenomena.152,167 We hypothesize that 6-MP and 6-TG treatment affect activity of antioxidant 
proteins which results in increased oxidative stress and consequently mitochondrial dysfunction, 
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Table 6.2: MS/MS analysis table for differentially regulated proteins identified by 
Q-TOF MS/MS analysis 
Footnotes:  
1
Mass 1 = Molecular mass of the protein observed in Mascot search.
2
Mascot score 2 = >40    
indicate identification or extensive homology (p < 0.05).
3 
Peptide matched 3 = Number of peptides matched 
with protein in MS/MS query.
4 




































1 Q9UBB4 53,5 5,12 82 3 4% ATX10 
 
1 MAAPRPPPAR LSGVMVPAPI QDLEALRALT ALFKEQRNRE 
TAPRTIFQRV  
51 LDILKKSSHA VELACRDPSQ VENLASSLQL ITECFRCLRN 
ACIECSVNQN  
101 SIRNLDTIGV AVDLILLFRE LRVEQESLLT AFRCGLQFLG 
NIASRNEDSQ  
151 SIVWVHAFPE LFLSCLNHPD KKIVAYSSMI LFTSLNHERM 
KELEENLNIA  
201 IDVIDAYQKH PESEWPFLII TDLFLKSPEL VQAMFPKLNN 
QERVTLLDLM  
251 IAKITSDEPL TKDDIPVFLR HAELIASTFV DQCKTVLKLA 
SEEPPDDEEA  
301 LATIRLLDVL CEMTVNTELL GYLQVFPGLL ERVIDLLRVI 
HVAGKETTNI  
351 FSNCGCVRAE GDISNVANGF KSHLIRLIGN 
LCYKNKDNQD KVNELDGIPL  
401 ILDNCNISDS NPFLTQWVIY AIRNLTEDNS QNQDLIAKME 
EQGLADASLL  
451 KKVGFEVEKK GEKLILKSTR DTPKP 
 
2 Q9UFU4 36,9 6,37 304 9 17% HNRH3 
 
1 MDWVMKHNGP NDASDGTVRL RGLPFGCSKE 
EIVQFFQGLE IVPNGITLTM  
51 DYQGRSTGEA FVQFASKEIA ENALGKHKER IGHRYIEIFR 
SSRSEIKGFY  
101 DPPRRLLGQR PGPYDRPIGG RGGYYGAGRG 
SMYDRMRRGG DGYDGGYGGF  
151 DDYGGYNNYG YGNDGFDDRM RDGRGMGGHG 
YGGAGDASSG FHGGHFVHMR  
201 GLPFRATEND IANFFSPLNP IRVHIDIGAD GRATGEADVE 
FVTHEDAVAA  
251 MSKDKNNMQH RYIELFLNST PGGGSGMGGS 
GMGGYGRDGM DNQGGYGSVG  
301 RMGMGNNYSG GYGTPDGLGG YGRGGGGSGG 
YYGQGGMSGG GWRGMY 
 
3 Q13011 35,8 8,16 174 6 14% ECH1 
 
1 MAAGIVASRR LRDLLTRRLT GSNYPGLSIS LRLTGSSAQE 
EASGVALGEA  
51 PDHSYESLRV TSAQKHVLHV QLNRPNKRNA 
MNKVFWREMV ECFNKISRDA  
101 DCRAVVISGA GKMFTAGIDL MDMASDILQP 
KGDDVARISW YLRDIITRYQ  
151 ETFNVIERCP KPVIAAVHGG CIGGGVDLVT 
ACDIRYCAQD AFFQVKEVDV  
201 GLAADVGTLQ RLPKVIGNQS LVNELAFTAR 
KMMADEALGS GLVSRVFPDK  
251 EVMLDAALAL AAEISSKSPV AVQSTKVNLL 
YSRDHSVAES LNYVASWNMS  
301 MLQTQDLVKS VQATTENKEL KTVTFSKL 
 
4 Q96Q81 26,7 9,65 111 4 12% DUT 
 
1 MTPLCPRPAL CYHFLTSLLR SAMQNARGTA EGRSRGTLRA 
RPAPRPPAAQ  
51 HGIPRPLSSA GRLSQGCRGA STVGAAGWKG 
ELPKAGGSPA PGPETPAISP  
101 SKRARPAEVG GMQLRFARLS EHATAPTRGS 
84 
 
ARAAGYDLYS AYDYTIPPME  
151 KAVVKTDIQI ALPSGCYGRV APRSGLAAKH FIDVGAGVID 
EDYRGNVGVV  




5 P23528 18,5 8,22 110 3 16% COF1 
 
1 MASGVAVSDG VIKVFNDMKV RKSSTPEEVK KRKKAVLFCL 
SEDKKNIILE  
51 EGKEILVGDV GQTVDDPYAT FVKMLPDKDC 
RYALYDATYE TKESKKEDLV  
101 FIFWAPESAP LKSKMIYASS KDAIKKKLTG IKHELQANCY 
EEVKDRCTLA  
151 EKLGGSAVIS LEGKPL 
 
 
6 P16949 17,3 5,76 181 5 29% STMN1 
 
1 MASSDIQVKE LEKRASGQAF ELILSPRSKE SVPEFPLSPP 
KKKDLSLEEI  
51 QKKLEAAEER RKSHEAEVLK QLAEKREHEK EVLQKAIEEN 
NNFSKMAEEK  




Q9P1F3 9 5,86 43 2 27% ABRAL  
1 MNVDHEVNLL VEEIHRLGSK NADGKLSVKF GVLFRDDKCA 
NLFEALVGTL  
51 KAAKRRKIVT YPGELLLQGV HDDVDIILLQ D 
 
8 P10599 11,7 4,82 244 10 40% THIO 
 
1 MVKQIESKTA FQEALDAAGD KLVVVDFSAT WCGPCKMIKP 
FFHSLSEKYS  
51 NVIFLEVDVD DCQDVASECE VKCMPTFQFF 
KKGQKVGEFS GANKEKLEAT  
101 INELV 
 
9 P07737 15 8,44 113 4 22% PROF1 
 
1 MAGWNAYIDN LMADGTCQDA AIVGYKDSPS 
VWAAVPGKTF VNITPAEVGV  
51 LVGKDRSSFY VNGLTLGGQK CSVIRDSLLQ 
DGEFSMDLRT KSTGGAPTFN  




10 P14174 12,5 4,74 175 4 17% MIF 
 
1 MPMFIVNTNV PRASVPDGFL SELTQQLAQA TGKPPQYIAV 
HVVPDQLMAF  
51 GGSSEPCALC SLHSIGKIGG AQNRSYSKLL CGLLAERLRI 
SPDRVYINYY  




11 P69905 15,2 8,72 31 1 6% HBA 
 
1 MVLSPADKTN VKAAWGKVGA HAGEYGAEAL 
ERMFLSFPTT KTYFPHFDLS 
 51 HGSAQVKGHG KKVADALTNA VAHVDDMPNA 
LSALSDLHAH KLRVDPVNFK  
101 LLSHCLLVTL AAHLPAEFTP AVHASLDKFL ASVSTVLTSK 
YR 
 
12 Q9BRA2 13,9 5,4 187 5 15% TXD17 
 
1 MARYEEVSVS GFEEFHRAVE QHNGKTIFAY FTGSKDAGGK 
SWCPDCVQAE  
51 PVVREGLKHI SEGCVFIYCQ VGEKPYWKDP 
NNDFRKNLKV TAVPTLLKYG  
101 TPQKLVESEC LQANLVEMLF SED
 
 
13 P58546 12,8 5,27 118 3 14% MTPN 
 
1 MCDKEFMWAL KNGDLDEVKD YVAKGEDVNR 
TLEGGRKPLH YAADCGQLEI  














Table 6.3: MS/MS analysis table for differentially regulated phospho proteins 
identified by Q-TOF MS/MS analysis 
Footnotes:  
1
Mass 1 = Molecular mass of the protein observed in Mascot search.
2 
Mascot score 2 = >40    
indicate identification or extensive homology (p < 0.05).
3 
Peptide matched 3 = Number of peptides matched 
with protein in MS/MS query.
4 




























































1 MDADDSRAPK GSLRKFLEHL SGAGKAIGVL TSGGDAQGMN 
AAVRAVVRMG  
51 IYVGAKVYFI YEGYQGMVDG GSNIAEADWE SVSSILQVGG 
TIIGSARCQA  
101 FRTREGRLKA ACNLLQRGIT NLCVIGGDGS LTGANLFRKE 
WSGLLEELAR  
151 NGQIDKEAVQ KYAYLNVVGM VGSIDNDFCG TDMTIGTDSA 
LHRIIEVVDA  
201 IMTTAQSHQR TFVLEVMGRH CGYLALVSAL ACGADWVFLP 
ESPPEEGWEE  
251 QMCVKLSENR ARKKRLNIII VAEGAIDTQN KPITSEKIKE 
LVVTQLGYDT  
301 RVTILGHVQR GGTPSAFDRI LASRMGVEAV IALLEATPDT 
PACVVSLNGN  
351 HAVRLPLMEC VQMTQDVQKA MDERRFQDAV 
RLRGRSFAGN LNTYKRLAIK  
401 LPDDQIPKTN CNVAVINVGA PAAGMNAAVR SAVRVGIADG 
HRMLAIYDGF  
451 DGFAKGQIKE IGWTDVGGWT GQGGSILGTK RVLPGKYLEE 
IATQMRTHSI  
501 NALLIIGGFE AYLGLLELSA AREKHEEFCV PMVMVPATVS 
NNVPGSDFSI  
551 GADTALNTIT DTCDRIKQSA SGTKRRVFII ETMGGYCGYL 
ANMGGLAAGA  
601 DAAYIFEEPF DIRDLQSNVE HLTEKMKTTI QRGLVLRNES 
CSENYTTDFI  
651 YQLYSEEGKG VFDCRKNVLG HMQQGGAPSP 
FDRNFGTKIS ARAMEWITAK  
701 LKEARGRGKK FTTDDSICVL GISKRNVIFQ PVAELKKQTD 
FEHRIPKEQW  
751 WLKLRPLMKI LAKYKASYDV SDSGQLEHVQ PWSV 
 
2 P40227 58 6,23 366 12 21% TCPZ 
1 MAAVKTLNPK AEVARAQAAL AVNISAARGL QDVLRTNLGP 
KGTMKMLVSG  
51 AGDIKLTKDG NVLLHEMQIQ HPTASLIAKV ATAQDDITGD 
GTTSNVLIIG  
101 ELLKQADLYI SEGLHPRIIT EGFEAAKEKA LQFLEEVKVS 
REMDRETLID  
151 VARTSLRTKV HAELADVLTE AVVDSILAIK KQDEPIDLFM 
IEIMEMKHKS 
 201 ETDTSLIRGL VLDHGARHPD MKKRVEDAYI LTCNVSLEYE 
KTEVNSGFFY  
251 KSAEEREKLV KAERKFIEDR VKKIIELKRK VCGDSDKGFV 
VINQKGIDPF  
301 SLDALSKEGI VALRRAKRRN MERLTLACGG VALNSFDDLS 
PDCLGHAGLV  
351 YEYTLGEEKF TFIEKCNNPR SVTLLIKGPN KHTLTQIKDA 
VRDGLRAVKN  
401 AIDDGCVVPG AGAVEVAMAE ALIKHKPSVK GRAQLGVQAF 
ADALLIIPKV  
451 LAQNSGFDLQ ETLVKIQAEH SESGQLVGVD LNTGEPMVAA 
EVGVWDNYCV  
501 KKQLLHSCTV IATNILLVDE IMRAGMSSLK G 
 
3 P31146 51 6,25 131 6 10% COR1A 
1 MSRQVVRSSK FRHVFGQPAK ADQCYEDVRV SQTTWDSGFC 
AVNPKFVALI  
51 CEASGGGAFL VLPLGKTGRV DKNAPTVCGH TAPVLDIAWC 
PHNDNVIASG  
101 SEDCTVMVWE IPDGGLMLPL REPVVTLEGH TKRVGIVAWH 
TTAQNVLLSA  
151 GCDNVIMVWD VGTGAAMLTL GPEVHPDTIY 
SVDWSRDGGL ICTSCRDKRV  
201 RIIEPRKGTV VAEKDRPHEG TRPVRAVFVS EGKILTTGFS 
RMSERQVALW  
251 DTKHLEEPLS LQELDTSSGV LLPFFDPDTN IVYLCGKGDS 
SIRYFEITSE  




351 TVPRKSDLFQ EDLYPPTAGP DPALTAEEWL GGRDAGPLLI 
SLKDGYVPPK  
401 SRELRVNRGL DTGRRRAAPE ASGTPSSDAV SRLEEEMRKL 
QATVQELQKR  
451 LDRLEETVQA K 
 
4 P50395 50,6 6,11 378 11 30% GDIB 
1 MNEEYDVIVL GTGLTECILS GIMSVNGKKV LHMDRNPYYG 
GESASITPLE  
51 DLYKRFKIPG SPPESMGRGR DWNVDLIPKF LMANGQLVKM 
LLYTEVTRYL  
101 DFKVTEGSFV YKGGKIYKVP STEAEALASS LMGLFEKRRF 
RKFLVYVANF  
151 DEKDPRTFEG IDPKKTTMRD VYKKFDLGQD VIDFTGHALA 
LYRTDDYLDQ  
201 PCYETINRIK LYSESLARYG KSPYLYPLYG LGELPQGFAR 
LSAIYGGTYM  
251 LNKPIEEIIV QNGKVIGVKS EGEIARCKQL ICDPSYVKDR 
VEKVGQVIRV  
301 ICILSHPIKN TNDANSCQII IPQNQVNRKS DIYVCMISFA 
HNVAAQGKYI  
351 AIVSTTVETK EPEKEIRPAL ELLEPIEQKF VSISDLLVPK 
DLGTESQIFI  
401 SRTYDATTHF ETTCDDIKNI YKRMTGSEFD FEEMKRKKND 
IYGED 
 
5 P61160 44,7 6,30 72 1 3% ARP2 
1 MDSQGRKVVV CDNGTGFVKC GYAGSNFPEH IFPALVGRPI 
IRSTTKVGNI  
51 EIKDLMVGDE ASELRSMLEV NYPMENGIVR NWDDMKHLWD 
YTFGPEKLNI  
101 DTRNCKILLT EPPMNPTKNR EKIVEVMFET YQFSGVYVAI 
QAVLTLYAQG  
151 LLTGVVVDSG DGVTHICPVY EGFSLPHLTR RLDIAGRDIT 
RYLIKLLLLR  
201 GYAFNHSADF ETVRMIKEKL CYVGYNIEQE QKLALETTVL 
VESYTLPDGR  
251 IIKVGGERFE APEALFQPHL INVEGVGVAE LLFNTIQAAD 
IDTRSEFYKH  
301 IVLSGGSTMY PGLPSRLERE LKQLYLERVL KGDVEKLSKF 
KIRIEDPPRR  
351 KHMVFLGGAV LADIMKDKDN FWMTRQEYQE 
KGVRVLEKLG VTVR 
 
6 P62333 44,1 7,10 244 10 27% PRS10 
1 MADPRDKALQ DYRKKLLEHK EIDGRLKELR EQLKELTKQY 
EKSENDLKAL  
51 QSVGQIVGEV LKQLTEEKFI VKATNGPRYV VGCRRQLDKS 
KLKPGTRVAL  
101 DMTTLTIMRY LPREVDPLVY NMSHEDPGNV SYSEIGGLSE 
QIRELREVIE  
151 LPLTNPELFQ RVGIIPPKGC LLYGPPGTGK TLLARAVASQ 
LDCNFLKVVS  
201 SSIVDKYIGE SARLIREMFN YARDHQPCII FMDEIDAIGG 
RRFSEGTSAD  
251 REIQRTLMEL LNQMDGFDTL HRVKMIMATN RPDTLDPALL 
RPGRLDRKIH  
301 IDLPNEQARL DILKIHAGPI TKHGEIDYEA IVKLSDGFNG 
ADLRNVCTEA  
351 GMFAIRADHD FVVQEDFMKA VRKVADSKKL ESKLDYKPV 
 
7 P78406 40,9 7,96 135 6 19% RAE1L 
1 MSLFGTTSGF GTSGTSMFGS ATTDNHNPMK DIEVTSSPDD 
SIGCLSFSPP  
51 TLPGNFLIAG SWANDVRCWE VQDSGQTIPK AQQMHTGPVL 
DVCWSDDGSK  
101 VFTASCDKTA KMWDLSSNQA IQIAQHDAPV KTIHWIKAPN 
YSCVMTGSWD  
151 KTLKFWDTRS SNPMMVLQLP ERCYCADVIY PMAVVATAER 
GLIVYQLENQ  
201 PSEFRRIESP LKHQHRCVAI FKDKQNKPTG FALGSIEGRV 
AIHYINPPNP  
251 AKDNFTFKCH RSNGTNTSAP QDIYAVNGIA FHPVHGTLAT 
VGSDGRFSFW  
301 DKDARTKLKT SEQLDQPISA CCFNHNGNIF AYASSYDWSK 
GHEFYNPQKK  




8 P09211 23,3 5,43 432 6 49% GSTM3 
1 MSCESSMVLG YWDIRGLAHA IRLLLEFTDT SYEEKRYTCG 
EAPDYDRSQW  
51 LDVKFKLDLD FPNLPYLLDG KNKITQSNAI LRYIARKHNM 
CGETEEEKIR  
101 VDIIENQVMD FRTQLIRLCY SSDHEKLKPQ YLEELPGQLK 
QFSMFLGKFS  
151 WFAGEKLTFV DFLTYDILDQ NRIFDPKCLD EFPNLKAFMC 
RFEALEKIAA  
201 YLQSDQFCKM PINNKMAQWG NKPVC 
 
9 P30048 27,6 7,67 113 6 22% PRDX3 
1 MAAAVGRLLR ASVARHVSAI PWGISATAAL RPAACGRTSL 
TNLLCSGSSQ  
51 AKLFSTSSSC HAPAVTQHAP YFKGTAVVNG EFKDLSLDDF 
KGKYLVLFFY  
101 PLDFTFVCPT EIVAFSDKAN EFHDVNCEVV AVSVDSHFSH 
LAWINTPRKN  
151 GGLGHMNIAL LSDLTKQISR DYGVLLEGSG LALRGLFIID 
PNGVIKHLSV  
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